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 Given the steady rise in obesity worldwide, it is important to identify dietary 
compounds that prevent adiposity. One dietary strategy is supplementation with 
conjugated linoleic acid (CLA), which has been demonstrated to reduce body fat mass.  
However, side effects associated with CLA supplementation include inflammation, 
insulin resistance, and dyslipidemia.  Elucidation of the antiobesity mechanism of CLA is 
critical for evaluating its efficacy and safety as a dietary supplement for treating obesity. 
Therefore, this research examined the upstream mechanism by which CLA induced 
inflammation, insulin resistance, and delipidation of human adipocytes.   
Our research group has previously demonstrated that trans-10, cis-12 (10,12) 
CLA causes delipidation of human adipocytes via activating nuclear factor kappa B 
(NFκB) and mitogen-activated protein kinase / extracellular signal-regulated kinase 
kinase (MEK/ERK) signaling, leading to inflammation and the suppression of 
peroxisome proliferator activated receptor (PPARγ) and decreased glucose and fatty acid 
uptake.  Based on these findings, the following questions were addressed using primary 
cultures of newly differentiated human adipocytes as a cell model 1) How does CLA 
impact PPARγ activity?, 2) What upstream mechanisms activate ERK, NFκB and induce 
inflammation?, and 3) Does resveratrol, a phenolic phytochemical with antioxidant 
properties, attenuate CLA-induced inflammation, insulin resistance, and delipidation? 
 Answers to these questions were as follows. 1) 10,12 CLA antagonized ligand-
dependent PPARγ activity, possibly via PPARγ phosphorylation by ERK.  10,12 CLA 
suppression of PPARγ  and insulin-stimulated glucose uptake, along with delipidation 
were partially rescued by co-supplementation with the PPARγ agonist BRL, further 
supporting CLA antagonizing PPARγ.  2) Cultures treated with TMB-8, an inhibitor of 
calcium release from the endoplasmic reticulum or KN-62, an inhibitor of 
calcium/calmodulin-dependent kinase II (CAMKII) attenuated 10,12 CLA-mediated 
reactive oxygen species (ROS) production, mitogen-activated protein kinase (MAPK) 
activation, inflammatory gene induction, and insulin resistance.  These data suggested 
that 10,12 CLA-mediated inflammation and insulin resistance are dependent on calcium 
release from the endoplasmic reticulum or CAMKII.  3) Treatment with resveratrol 
prevented 10,12 CLA-mediated inflammation and insulin resistance by attenuating 
intracellular calcium, ROS,  and inflammation, by increasing PPARγ activity.  
Collectively, these data suggest that one of the antiobesity mechanisms of 10,12 CLA is 
inducing cellular stress and inflammation which antagonize PPARγ, leading to insulin 
resistance and delipidation of human adipocytes. 
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CHAPTER I 
 
 
INTRODUCTION
 
 
 
Overview 
Obesity rates have risen in the U.S. over the past 20 years.  In 2007, the CDC 
estimated that of the 51 states in the U.S., 30 had rates of obesity greater than 25% based 
on a body mass index (BMI) greater than 30 (CDC 2007).   Obesity is the leading risk 
factor for developing chronic diseases such as type 2 diabetes, stroke, cancer, and 
cardiovascular disease.  These metabolic disorders are major health concerns in the U.S., 
especially among minority populations. This has resulted in the U.S. spending ~100 
billion dollars on medical expenses related to obesity.  Although reducing caloric intake 
relative to energy expenditure and increasing physical activity are established means for 
preventing or treating obesity, the incidence of obesity among children, adolescents, and 
adults continues to increase dramatically.  Therefore, research has been aimed at 
identifying alternative strategies that prevent or attenuate adiposity, and identify 
underlying mechanisms impacting the growth, differentiation, or metabolism of 
adipocytes, the main cell types in white adipose tissue (WAT).  
One potential strategy for reducing adiposity is dietary supplementation with 
conjugated linoleic acid (CLA), an unsaturated fatty acid naturally found in ruminant 
meats and dairy products (Fig. 1.1).  Numerous animal studies and several human studies 
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have demonstrated that supplementation with a mixture of trans-10, cis-12 (10,12) and 
cis-9, trans-11 (9,11) isomers of CLA, or 10,12 CLA alone, reduces body weight and fat 
deposition. Precisely how CLA reduces adiposity remains unclear, and thus will be the 
focus of this dissertation.   
Our research group has demonstrated that 10,12 CLA, but not 9,11 CLA, 
decreases fatty acid and glucose uptake and triglyceride (TG) synthesis  in primary 
cultures of human adipocytes by activating mitogen-activated protein kinase / 
extracellular signal-regulated kinase kinase (MEK/ERK) and nuclear factor kappa B 
(NFκB) signaling that induces interleukin (IL)-6, IL-8, and tumor necrosis factor (TNF) α 
production.  These cytokines, in turn, attenuate peroxisome proliferator activated receptor 
(PPAR) γ target gene expression in adipocytes, reducing glucose and fatty acid uptake.  
The mechanism by which 10,12 CLA produces upstream signals that activate NFκB and 
ERK1/2, and cause delipidation and insulin resistance is unknown.  Elucidating this 
mechanism will provide valuable information on the efficacy, specificity, and potential 
side effects of CLA isomers as a dietary strategy for preventing or treating obesity.  Lack 
of such knowledge is an important problem, because until it becomes available, the 
effective and safe use of CLA supplements to control obesity can not ensue.   
Central Hypothesis and Specific Objectives 
The central hypothesis for the proposed research is that 10,12 CLA elevates the 
levels of intracellular calcium [Ca2+]i and reactive oxygen species (ROS),  which lead to 
the activation of calcium/calmodulin-dependent protein kinase II (CAMKII), MEK/ERK, 
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and NFκB-induced inflammation, resulting in the suppression of PPARγ activity and 
target gene expression, insulin resistance, and delipidation in primary cultures of human 
adipocytes.      
To test this hypothesis, the following three specific aims were investigated using 
primary cultures of newly differentiated human adipocytes. 
1. Determine the mechanism by which 10,12 CLA suppresses the expression of 
PPARγ and its target genes (Chapter III).   
2. Identify upstream mechanism(s) by which 10,12 CLA induces inflammation, 
and insulin resistance (Chapter IV).     
3. Determine the extent to which resveratrol prevents 10,12 CLA induced 
cellular stress, inflammation, insulin resistance and delipidation (Chapter V). 
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Figure 1.1.  Conjugated linoleic acid isomers (CLA).   
From Am. J. Clin. Nutr. 2004:79 p1132S-1136S 
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CHAPTER II 
 
 
REVIEW OF THE LITERATURE
 
 
 
Background and Significance 
Conjugated linoleic acid (CLA) refers to a group of conjugated octadecadienoic 
acid isomers found in ruminant meats and dairy products. Conjugated linoleic acid is a 
derivative of linoleic acid, which contains 18 carbons and two double bonds in the cis 
configuration at the 9th and 12th carbons, i.e., cis-9, cis-12 octadecadienoic acid. In the 
gastrointestinal tract of ruminant animals, microbes convert linoleic acid into different 
isoforms of CLA through biohydrogenation. This process changes the position and 
configuration of the double bonds, resulting in a single bond between one or both of the 
two double bonds; i.e. cis-9, trans-11 (9,11) or trans-10, cis-12 (10,12) octadecadienoic 
acid. 
Commercially, CLA is produced from linoleic acid derived from safflower or 
sunflower oils in the presence of alkaline substances. This type of processing yields a 
CLA mixture containing ~40% of the 9,11 isomer and 44% of the 10,12 isomer 
(reviewed in Pariza et al. 2001). Commercial preparations also contain ~4-10% trans-9, 
trans-11 CLA and trans-10, trans-12 CLA, as well as trace amounts of other isomers. 
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In natural foods, the predominant form of CLA is the 9,11 isomer, also known as 
rumenic acid.  9,11 CLA makes up ~ 90% of CLA found in ruminant meats and dairy 
products, with the remaining 10% of CLA as the 10,12 isomer. Although several other 
isoforms of CLA have been identified (i.e., trans-9, trans-11; cis-9, cis-11; trans-10, 
trans-11; and cis-10, cis-12), the 9,11 and 10,12 isomers appear to be the most 
biologically active (Wallace et al. 2007).  
The content of CLA in milk and other dairy products ranges between ~0.34 – 
1.07% total fat, and from 0.12 – 0.68% total fat in raw or processed beef products 
(reviewed in Dhiman et al. 2005 and Silveira et al. 2007, Mendis et al. 2008). However, 
the CLA content of beef is dependent on several factors including the breed, season, 
nutrition, and age of the animal (reviewed Dhiman et al. 2005). The average daily intake 
of CLA is ~152 and 212 mg for non-vegetarian women and men, respectively 
(Ritzenthaler et al. 2001).  Physiological levels in human serum range from 10 to 70 
μmol/L (Mougios et al. 2001, Petridou et al. 2003).  
Antiobesity properties of CLA 
CLA was initially discovered in 1987 by Pariza and colleagues and it was 
identified to be an anti-carcinogen (Hay et al. 1987). Subsequently, CLA was shown to 
exhibit anti-atherosclerotic (reviewed in Mitchell et al. 2008) and anti-obesity properties 
(reviewed in Whigham et al. 2007).  Due to the substantial rise of obesity prevalence over 
the past 30 years (CDC 2008), more interest in CLA has developed for its use as a weight 
loss treatment.  For example, supplementation with a CLA mixture (i.e., 10,12 + 9,11 
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isomers in equal concentrations) or the 10,12 isomer at ~3-6 g/d decreases body fat mass 
(BFM) in animals and some humans (reviewed in Wang et al. 2004 and Whigham et al. 
2007).  Of the two major isomers of CLA, the 10,12 isomer possess most of the anti-
obesity properties compared to the 9,11 isomer (Park et al. 1999, Brown et al. 2001, 
House et al. 2005, Brandebourg et al. 2005, Miller et al 2008).  
CLA regulation of body weight 
Park et al. (1997) were the first to demonstrate that CLA modulated body 
composition. Compared to controls, male and female mice supplemented with a 0.5% 
(w/w) CLA mixture had 57 and 60% less BFM, respectively. Since these findings, 
researchers have demonstrated that CLA supplementation consistently reduces BFM in 
mice, rats, and pigs (Sisk et al. 2001, Clement et al. 2002, Meadus et al. 2002, Yamasaki 
et al. 2003, Poirier et al. 2006). For example, dietary supplementation with 1% (wt/wt) 
CLA mixture for 28 d decreased body weight and peri-uteral white adipose tissue (WAT) 
mass in C57BL/6J mice (Poirier et al. 2005). Dietary supplementation with a 1.5% 
(wt/wt) mixture of CLA for 4 wk decreased body weight and WAT mass in male ob/ob 
mice (Wendel et al.  2008).    
CLA reduces BFM in animals more consistently than in humans.  Whereas some 
studies show that CLA decreases BFM and increases lean body mass (LBM) (reviewed in 
Wang et al. 2004 and House et al. 2005), others have shown no effect of CLA 
supplementation on body composition in humans (reviewed in Wang et al. 2004). For 
example, supplementation of 3-4 g/d of a CLA mixture for 24 wk decreased BFM and 
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increased LBM in overweight and obese people (Gaullier et al. 2007). On the other hand, 
supplementation of 3.76 g/d of a CLA mixture in yogurt for 14 wk in healthy adults had 
no effect on body composition (Nazare et al. 2007). Larsen et al. (2006) investigated the 
potential role of CLA for preventing body weight regain in moderately obese subjects 
who lost ~10 kg after an 8-wk dietary intervention on a low calorie diet. Supplementation 
for 1 year with a CLA mixture did not prevent body weight regain compared to controls. 
Laso et al. (2007) found that supplementation with 3.2 g/d of a CLA mixture decreased 
total BFM and trunk fat compared to placebo in overweight subjects, but not obese 
subjects. These contradictory findings among human studies may be due to the following 
differences in experimental design 1) mixed vs. individual CLA isomers, 2) CLA dose 
and duration of treatment, and 3) gender, weight, age and metabolic status of the subjects.   
The main discrepancy between animal and human studies may be due to the dose 
of CLA used. For example, moderately overweight humans with an average weight of 
72.5 kg supplemented with 3.76 g of a CLA mixture per d for 14 wk displayed no 
decrease in body weight, BMI, or BFM (Nazare et al. 2007).  In contrast, C57BL/6 mice 
supplemented with 1.5% (w/w) CLA mixture for 4 wk weighed less than controls 
(Purushotham et al. 2007). However, when comparing the amount of CLA given on a 
body weight basis (g CLA consumed/ kg body weight), humans in Nazare’s study 
received ~0.05 g/kg body weight, whereas mice in Purushotham’s study received 1.07 
g/kg body weight. Thus, the mice received ~20 times more CLA per kg body weight than 
the human subjects. 
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Based on CLA’s potential to reduce BFM, it is important to understand the 
mechanism of action of CLA.  Therefore, this literature review will examine potential 
mechanisms by which the CLA mixture or 10,12 CLA alone reduces adiposity, with 
particular emphasis on WAT.  Potential mechanisms to be discussed include CLA 
regulating 1) energy metabolism, 2) adipogenesis, 3) lipid metabolism, 4) inflammation, 
and 5) apoptosis.  Some data presented in the next sections were taken from Chapters III-
V to demonstrate how my research integrates with the current literature on CLA.  
Antiobesity Mechanisms of Conjugated Linoleic Acid 
CLA regulation of energy metabolism 
CLA decreases energy intake.  Energy balance is a function of energy intake relative to 
energy expenditure. When energy intake exceeds energy expenditure, body weight and 
BFM increase, and vice versa.  One proposed mechanism by which CLA reduces BFM is 
by decreasing energy intake or increasing energy expenditure (Fig. 1).  Park et al.  (1997) 
were the first to demonstrate that supplementation of mice with a CLA mixture or 
enriched 10,12 CLA for 4 wk reduced food intake.  There are a number of studies 
demonstrating that feeding a CLA mixture reduces energy intake in rodents (Miner et al. 
2001, Hargrave et al. 2002, Takahashi et al. 2002, House et al. 2005, So et al. 2009).  
However, CLA does not appear to decrease food intake in humans (Zambell 2000, 
Medina 2000, Lambert et al. 2007, Tholstrup et al 2008).    
So et al. (2009) reported that food intake was reduced by 23.6% in mice fed a 
low-fat diet supplemented with 10,12 CLA.  The hypothalamic gene expression ratio of 
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proopiomelancortin (POMC) to neuropeptide Y (NPY) was decreased by 10,12 CLA 
supplementation, suggesting CLA reduced food intake through suppression of 
hypothalamic appetite-regulating genes.  In support of these findings, administration of 
mixed isomers of CLA to the hypothalamus decreased the gene expression of NPY and 
agouti-related protein, neuropeptides that robustly increase food intake (Cao et al. 2007).  
Alternatively, CLA could be reducing the palatability of the diet or increasing satiety. 
In contrast, a number of studies have reported no changes in energy intake 
following administration of a CLA mixture in mice (Azain et al. 2000, West et al. 2000, 
Terpstra et al. 2002, Terpstra et al. 2003,).  For example, supplementation of mice with a 
CLA mixture for 42 d decreased total body weight, without reducing food intake 
(Terpstra et al. 2003).  These data suggest that CLA suppression of body fat is not solely 
dependent on reductions of food or energy intake. 
CLA increases energy expenditure.  Energy expenditure is a function of basal metabolic 
rate (BMR), adaptive thermogenesis, and physical activity.  CLA has been proposed to 
reduce adiposity by elevating energy expenditure (Fig. 1) via increasing BMR, 
thermogenesis, or lipid oxidation in animals (West et al. 2000, Miner et al. 2001, Ohnuki 
et al. 2001, Terpstra et al. 2002, Terpstra et al. 2003, Nago et al. 2003).    In BALB/c 
male mice fed mixed isomers of CLA for 6 wk, body fat was decreased by 50% and was 
accompanied by increased energy expended as heat as compared to controls (Terpstra et 
al. 2003).  Enhanced thermogenesis is associated with mitochondria uncoupling.  During 
uncoupling, trans-membrane proteins known as uncoupling proteins (UCP), which span 
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the inner mitochondrial membrane, uncouple the oxidation of fuels to ATP formation, 
leading to dissipation of energy as heat instead of ATP synthesis. UCP2 is the most 
abundant and active form in WAT, while UCP1 and 3 are primarily expressed in brown 
adipose tissue (reviewed in Ricquier et al. 2000).  Supplementation with a CLA mixture 
or 10,12 CLA in rodents induced UCP 2 gene expression in WAT (Takahashi et al. 2002, 
Ealey et al. 2002, Kang et al. 2004, House et al. 2005, LaRosa et al. 2006).  CLA 
increased the expression of carnitine palmitoyl transferase 1 (CPT1), an important 
enzyme in the FA oxidation in WAT (Martin et al. 2000, LaRosa et al. 2006).  Consistent 
with these findings, 10,12 CLA increased beta oxidation in 3T3-L1 preadipocytes (Evans 
et al. 2002).  Similarly, CLA supplementation induced UCP gene expression and elevated 
beta oxidation in muscle and liver (Takahashi et al. 2002, Roche et al. 2002, Choi et al. 
2007, Ribot et al. 2007, Prior et al. 2007, Ferramosca et al. 2008). 
 Activation of UCP decreases the ATP/ADP ratio, which stimulates the activation 
of 5’-AMP-activated protein kinase (AMPK) (reviewed in Rossmeisl et al. 2004).  
Activated AMPK can phosphorylate hormone sensitive lipase (HSL), leading to 
activation of lipolysis in WAT (Anthony et al. 2009), and phosphorylation of acetyl CoA 
carboxylase (ACC), resulting in suppression of lipogenesis in isolated white adipocytes 
(Gaidhu et al. 2008) (Fig. 2).  Supplementation of ob/ob mice with 1.5% (w/w) CLA 
mixture for 6 wk increased AMPK activity in WAT compared to controls (Wendel et al. 
2007), although UCP-1 and CPT1 gene expression were not induced.  While there are 
limited studies demonstrating that CLA activates AMPK, ACC mRNA levels were 
decreased in adipocytes treated with 10,12 CLA (Brown et al. 2003).  Consistent with 
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these findings 10,12 CLA inhibited lipogenesis (Brown et al. 2004) and increased acute 
lipolysis in cultures of newly differentiated human adipocytes (Chung et al. 2005a).       
Results from human studies concerning CLA regulation of energy expenditure are 
mixed.  For example, supplementation of humans with 3.9 g/d of CLA mixture for 12 wk 
did not alter BMR or alter BFM (Lambert et al. 2007).  Similar findings have been 
reported in humans supplemented with a CLA mixture (Zambell et al. 2000, Steck et al. 
2007).  In contrast, healthy, moderately-overweight humans supplemented with 3.76 g/d 
CLA mixture in yogurt for 14 wk had higher BMR levels, but had no differences in UCP 
2 gene expression in WAT or altered body weight (Nazare et al. 2007).  Similarly, resting 
metabolic rate and fat-free mass were higher in humans supplemented with CLA mixture 
for 13 wk, but CLA had no effect on BFM (Kamphuis et al. 2003).  Thus far, only one 
human study has demonstrated that CLA increases energy expenditure and decreases 
body weight (Close et al. 2007).  In this study, humans supplemented for 6 mo with 4 g/d 
of a CLA mixture had decreased body weight and increased fat oxidation and energy 
expenditure while sleeping.                
Other studies have demonstrated that CLA supplementation increases LBM, 
which is associated with higher levels of energy expenditure.  For example, healthy obese 
humans supplemented with 6.4 g/d CLA mixture for 12 wk had increased LBM by 0.64 
kg compared to controls (Steck et al. 2007).   Similarly, mice fed a 0.4% (w/w) CLA 
mixture had increased LBM compared to controls (Bhattacharya et al. 2005).  Two 
proposed mechanisms by which CLA increases LBM are via increasing bone or muscle 
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mass. 10,12 CLA supplementation for 10 wk with a 0.5% (wt/wt) CLA mixture increased 
bone mineral density (BMD) and muscle mass in C57BL/6 female mice.  CLA 
supplementation has been proposed to increase BMD via increasing osteogenic gene 
expression and decreasing osteoclast activity (Banu et al. 2006, Rahman et al 2007).  
Furthermore, CLA supplementation alone or with exercise increased BMD compared to 
control mice (Banu et al. 2008).  An alternative mechanism could be that CLA decreases 
adipogenesis of pluripotent mesenchymal stem cells (MSC) in bone marrow, and instead 
enhances their commitment to become bone cells.  Indeed, 10,12 CLA has been shown to 
decrease the differentiation of MSC into adipocytes and increase calcium deposition and 
markers of osteoblasts (Platt et al. 2008).  In contrast, 9,11 CLA increased adipocyte 
differentiation and decreased osteoblast differentiation.  Consistent with these in vitro 
data, CLA mixture supplementation of rats treated with corticosteroids, which decrease 
muscle and bone mass, prevented reductions in LBM, BMD, and bone mineral content 
(Roy et al. 2008). Collectively, these findings suggest CLA may reduce adiposity through 
increased energy expenditure via increased UCP and CPT1 activity in WAT or increased 
muscle or bone mass.  However, the extent to which CLA regulates BMR or LBM, and 
how this contributes to the reduction in body weight or fat in humans, remains to be 
determined. 
CLA regulation of adipogenesis 
CLA inhibits adipogenesis.  The conversion of preadipocytes to adipocytes 
involves the activation of key transcription factors such as CAAT/ enhancer binding 
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proteins (C/EBPs) and peroxisome proliferators-activated receptor (PPAR)γ.   During the 
differentiation process, increased C/EBPβ and δ activity promote the activation of 
C/EBPα and PPARγ, the master regulators of adipocyte differentiation (Fig. 3).  There is 
much evidence showing that CLA suppresses preadipocyte differentiation in animal 
(Brodie et al. 1999, Satory et al. 1999, Choi et al. 2000, Evans et al. 2000, Granlund et al. 
2003, Kang et al. 2003, Miller et al. 2008) and human preadipocytes (Brown et al. 2003, 
Brown et al. 2004) treated with a CLA mixture or 10,12 CLA alone.  10,12 CLA 
treatment has been reported to decrease the expression of PPARγ, C/EBPα, sterol 
regulatory element binding protein 1c (SREBP-1c), liver X receptor (LXRα), and 
adipocyte fatty acid binding protein (aP2),  thereby reducing adipogenesis or lipogenesis 
(Brown et al. 2003, Kang et al. 2003, Granlund et al. 2005, House et al. 2005, LaRosa et 
al. 2007).  
In rodents, supplementation of 10,12 CLA decreased the expression of PPARγ 
and its target genes (Kang et al. 2003, LaRosa et al. 2006, Liu et al. 2007). In contrast, 
humans supplemented with a CLA mixture had higher mRNA levels of PPARγ in WAT, 
but no difference in body weight or BFM (Nazare et al. 2007).   
Reduced PPARγ protein levels were reported in cultures of newly differentiated 
human and 3T3-L1 adipocytes, respectively, when treated with 10,12 CLA as compared 
to 9,11 CLA (Kennedy et al. 2008-Chapter III, Miller et al. 2008).  While 10,12 CLA has 
been demonstrated to suppress PPARγ gene expression and protein level, data are 
inconclusive on CLA regulation of PPARγ activity.  Several CLA isomers, including 
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9,11, have been shown to activate PPARγ (Yu et al. 2002, Granuland et al 2003).  In 
contrast, in the presence of a PPARγ agonist such as rosiglitazone or darglitazone, CLA 
isomers have been reported to decrease the activity of the liver X receptor (LXRα)-
PPRE-LUC reporter (Granuland et al. 2003) and the acyl-CoA binding protein (ACBP)-
PPRE-LUC reporter (Brown et al. 2003) in 3T3-L1 adipocytes.  Recently, we reported 
that under ligand-stimulated conditions, PPRE-LUC reporter activity was decreased in 
the presence of 50 μmol/L 10,12 CLA compared to 9,11 CLA (Kennedy et al. 2008).  
Similarly, Miller et al. 2008 demonstrated in CHO-K1 cells that 100 μmol/L and 200 
μmol/L 10,12 CLA antagonized troglitazone activation of a PPRE reporter.  CLA 
suppression of PPARγ and target genes was also attenuated by rosiglitazone in vivo and 
in vitro (Liu et al. 2007, Kennedy et al. 2008), further supporting CLA antagonism of 
PPARγ function.   
PPARγ activity may also be impacted by phosphorylation.  Phosphorylation of 
Ser-112 of PPARγ2 leads to ubiquination and proteosome degradation of PPARγ (Hu et 
al. 1996).  PPARγ phosphorylation can occur by activation of mitogen activated kinase 
(MAPK) pathway, which has been demonstrated to inhibit adipogenesis (Diradourian et 
al. 2005).  We demonstrated that 10,12 CLA increases phosphorylation of ERK and 
PPARγ  (Kennedy et al. 2008), suggesting ERK may play a role in phosphorylating and 
inactivating PPARγ.    Consistent with these data, Brown et al. (2004) demonstrated that 
ERK activation is a key player in CLA’s suppression of adipogenic gene expression and 
insulin-stimulated glucose uptake.  Therefore, it is tempting to speculate that CLA 
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antagonizes PPARγ activity, possibly via activation of MAPKs like ERK, thereby 
suppressing (pre)adipocyte differentiation (Fig. 4).  However, the impact of CLA on the 
activity of other transcription factors involved in adipogenesis and lipogenesis (i.e., 
LXRα, C/EBPs, SREBP-1c) may also contribute to CLA’s anti-obesity actions.         
CLA regulation of lipid metabolism 
CLA suppresses lipogenesis.  Storage of FA as TG is a major function of adipocytes.  
Genes involved in lipogenesis, such as a lipoprotein protein lipase (LPL), ACC, fatty acid 
synthase (FAS), and stearoyl-CoA desaturase (SCD), were decreased following 
supplementation with mixed isomers of CLA or 10,12 CLA alone (Fig. 4) (Evans et al. 
2000, Brown et al. 2003, Brown et al. 2004, LaRosa et al. 2006).  PPARγ is a major 
regulator of LPL, and LPL gene expression decreased in adipocytes treated with 10,12 
CLA (Xu et al. 2003, Kennedy et al. 2008).  Consistent with the important role of LPL in 
delivery of FAs for TG synthesis in adipocytes, 10,12 CLA treatment decreased FA 
uptake in human adipocytes (Brown et. al 2004, Kennedy et al. 2009-Chapter V).  Thus, 
the anti-lipogenic actions of CLA may be partially due to decreased PPARγ activity.   
The major function of SCD is to synthesize oleate and palmitoleate, 
monounsaturated FAs important for neutral lipid and phospholipid synthesis from 
stearate and palmitate.  Reduced levels of monunsaturated FAs have been reported 
following treatment with a CLA mixture or 10,12 CLA in vivo (House et al. 2005, Martin 
et al. 2007) and in vitro (Brown et al. 2003). It has also been demonstrated that body fat 
loss in mice fed a CLA mixture is dependent on Δ6-desaturase (Hargrave-Barnes et al. 
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2008).  However, in SCD-1 knockout mice, 10,12 CLA supplementation reduced body 
weight along with increasing the ratio of 16:0/16:1 and decreasing the ratio of 18:0/18:1 
(Kang et. al. 2004), suggesting the antiobesity properties of CLA are not entirely 
dependent on SCD-1.    
CLA causes insulin resistance.  Insulin-stimulated glucose uptake in WAT is typically 
mediated via the insulin-dependent glucose transporter GLUT4.  Defects in insulin 
signaling or suppression of GLUT4 translocation to the plasma membrane are major 
causes of insulin resistance in adipocytes, leading to reduced TG synthesis (Fig. 5).  
Insulin resistance has been reported in vivo (Riserus et al. 2002, Moloney et al. 2004, La 
Rosa et al. 2006, Thrush et al. 2007, Ingelsson et al. 2008) and in vitro (Brown et al. 
2003, Chung et al. 2005b, Kennedy et al. 2008, Kennedy et al. 2009) following 
supplementation with a CLA mixture or 10,12 CLA alone.    In vivo, supplementation 
with a CLA mixture or 10,12 CLA has been shown to induce hyperinsulinemia 
(Reviewed in Wang et al. 2004).  Mechanisms by which CLA induces insulin resistance 
include inhibiting insulin signaling, increasing ceramide levels, or reducing the 
expression of genes (i.e, adiponectin, GLUT4) or activation of proteins (i.e, GLUT4, 
AKT, IRS-1) involved in glucose uptake.   
 CLA has been reported to inhibit insulin signaling via increasing the expression of 
suppressor of cytokine signaling (SOCS)-3 in 3T3-L1 (Poirier et al. 2006) and cultures of 
newly differentiated human adipocytes (Kennedy et al. 2009).  SOCS-3 promotes 
phosphorylation of serine 307 on insulin receptor substrate (IRS-1), leading to its 
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ubiquination and proteosome degradation, thereby impairing insulin signaling and 
glucose uptake (Ueki et al. 2004).  Treatment with 10,12 CLA has been demonstrated to 
decrease the protein levels of insulin receptor (IR)β (Poirier et al. 2006) and IRS-1 
(Chung et al. 2005b, Poirier et al. 2006), key signaling proteins for insulin sensitivity.  
10,12 CLA treatment decreased tyrosine phosphorylation of IRβ and IRS-1 in 3T3-L1 
adipocytes (Poirier et al. 2006). However, 10,12 CLA treatment in human and 3T3-L1 
adipocytes did not increase phosphorylation of Serine 307 on IRS-1 (Chung et al. 2005b, 
Poirier et al. 2006).  CLA reduced the gene expression of GLUT4 and SLC2A5, which is 
a glucose/fructose transporter member, in WAT and 3T3-L1 adipocytes supplemented 
with 10,12 CLA  (LaRosa et al. 2006).  In cultures of newly differentiated human 
adipocytes 10,12, but not 9,11, CLA decreased GLUT4 gene and protein expression 
(Brown et al. 2004, Chung et al. 2005b, Kennedy et al. 2008). These data suggest that 
10,12 CLA may impair insulin signaling by suppressing the levels of proteins involved in 
the signaling cascade. 
 The mRNA levels of adiponectin, a key adipokine associated with insulin 
sensitivity, decreases following supplementation with 10,12 CLA in vivo (Poirier et al. 
2006, Liu et al. 2007) and in vitro (Ahn et al. 2006, Perez-Matute et al. 2007, Kennedy et 
al. 2009, Miller et al. 2008).    Adiponectin is a known target gene of PPARγ (Iwaki et al. 
2003).  Therefore, suppression of adiponectin expression maybe due in part, to 10,12 
CLA antagonizing PPARγ activity.  Supplementation of rosiglitazone, a PPARγ agonist, 
prevented CLA suppression of adiponectin serum levels and CLA induced insulin 
resistance in mice (Liu et al.  2007).  Although treatment of 3T3-L1 adipocytes with 
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triglitazone prevented 10,12 CLA suppression of TG levels and adiponectin oligomer 
assembly, it did not prevent 10,12 CLA suppression of adiponectin synthesis (Miller et al.  
2008).  These data suggest that CLA suppression of adiponectin levels maybe indirectly 
related to its TG lowering actions in adipocytes. 
CLA stimulates lipolysis.  Lipolysis is the process by which stored TG is mobilized, 
releasing free fatty acids (FFA) and glycerol for use by metabolically-active tissues.  
Typically, when energy demand is increased, lipolysis is increased via cAMP-mediated 
signaling (Fig. 6).  LaRosa et al. (2006) demonstrated that C57BL/6J mice fed 10,12 
CLA for 3 d had increased mRNA levels of  HSL, a key enzyme involved in liberating 
FFA from TG stores.  However, HSL levels decreased following chronic (17 d) 
treatment.  Consistent with these data, acute treatment with CLA mixture or 10,12 CLA 
alone increased lipolysis in 3T3-L1 (Park et al. 1997, Evans et al. 2002, Moon et al. 
2006) and newly differentiated human adipocytes (Chung et al. 2005a).   
In contrast, in vivo studies have demonstrated that chronic supplementation with a 
mixture of CLA has no effect on lipolysis (Xu et al. 2003, Simon et al. 2005).  Chronic 
treatment with 1-200 μmol/L mixed isomer of CLA reduced glycerol release in isolated 
rat adipocytes (Perez-Matute et al. 2008).  Similarly, chronic treatment with 10,12 CLA 
decreased HSL gene expression (Brown et al. 2003) and protein levels (Chung et al. 
2005a).  Feeding hamsters a high fat diet supplemented with 0.5% (w/w) 10,12 CLA for 
3 wk had no effect on WAT HSL or TG lipase expression or body weight (Lasa et al. 
2008).  Consistent with these data, FFA levels have been reported to be lower in the 
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serum of OLETF rats supplemented with 1.0% (w/w) CLA mixture compared to controls 
(Rahman et al. 2001).  However, this reduction of FFA may be due to increased uptake of 
FFA in liver or muscle.  For example, supplementation with a CLA mixture or 10,12 
CLA alone increased lipid accumulation in the liver of mice (Andreoli et al. 2008, 
Oikawa et al. 2008) and hamsters (Tarling et al. 2008, Navarro et al. 2009). Thus, CLA 
may acutely induce lipolysis in WAT, liberating FFA for uptake in metabolically-active 
tissue (i.e., liver and muscle).  Lack of a chronic effect may be due to depleted TG stores 
in WAT.  This potential scenario, however, could lead to ectopic lipid accumulation 
similar to lipodystrophy syndromes. 
CLA increases inflammation.  WAT not only functions to store TG, but produces a 
number of pro-inflammatory cytokines (i.e., interleukin [(IL)]-1β, IL-6, TNFα, and 
interferon [(IFN)]-γ) that cause insulin resistance and suppress lipid synthesis in 
adipocytes.  Induction of these inflammatory genes is driven by MAPKs and transcription 
factors such as NFκB, which have been reported to antagonize PPARγ, thereby altering 
adipocyte function (Fig. 7).  Indeed, TNFα stimulates lipolysis and inhibits lipogenesis 
(Kawakami et al. 1987).  TNFα induces delipidation in adipocytes by suppression of 
glycerol 3-phosphate dehydrogenase (GPDH) and reduction of lipid droplet mass 
(Petruschke et al. 1993).  Similarly, IL-1β and IFNγ were observed to induce delipidation 
of human adipocytes (Simons et al. 2007).  Treatment with 10,12 CLA increases the 
expression or secretion of  TNFα, IL-1β, IL-6, and IL-8 (Brown et al. 2004, Chung et al. 
2005b, Poirier et al. 2006, LaRosa et al. 2006, Kennedy et al. 2009), which are known to 
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antagonize PPARγ activity and insulin sensitivity, thereby causing delipidation (Chung et 
al. 2006, Kennedy et al. 2008, Lui et al. 2007, Purushotham et al. 2007).  Similarly, 10,12 
CLA decreased GPDH mRNA levels (Brown et al. 2004) and attenuated the TG content 
of newly differentiated human adipocytes (Brown et al. 2004, Kennedy et al. 2008) and 
3T3-L1 adipocytes (LaRosa et al. 2007).   
In humans, 10,12 CLA supplementation increase the levels of inflammatory 
prostaglandins (PG)s and cytokines (Steck et al. 2007, Riserus et al. 2002, Raff et al. 
2008).  For example, women supplemented with 5.5 g/d of a CLA mixture for 16 wk had 
higher levels of C-reactive protein in serum and 8-iso-PGF2α in urine (Tholstrup et al. 
2008).   The expression of cyclooxygenase 2 (COX-2), an enzyme involved in the 
synthesis of PGs, was elevated in cultures of newly differentiated human adipocytes 
treated with 10,12 CLA (Kennedy et al. 2009).  Furthermore, 10,12 CLA increased 
PGF2α secretion from human adipocytes (Kennedy et al. 2009).  Inflammatory PGs such 
as PGF2α have been reported to inhibit adipogenesis through phosphorylation of PPARγ 
(Liu et al. 2007, Reginato et al. 1998).   
10,12 CLA induction of inflammatory genes appears to be dependent on the 
activation of MEK/ERK (Brown et al. 2004) and NFκB (Chung et al. 2005b, Poirier et al. 
2006) signaling in adipocytes.  Inflammatory signals or oxidative stress can induce 
translocation of NFκB (p65, p50) to the nucleus.  NFκB can then bind directly to PPARγ 
or co-activators, or prevent co-repressor dispersion, thereby blocking DNA binding of the 
PPARγ/RXR heterodimer to target genes, thereby inhibiting adipogenesis (Takada et al. 
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2005, reviewed in Ye et al. 2008).   Activation of ERK and NFκB were reported to be 
involved in 10,12 CLA suppression of adipogenic genes and insulin-stimulated glucose 
uptake (Brown et al. 2004, Chung et al. 2005b).  Taken together, these data suggest that 
10,12 CLA increases the production of inflammatory PGs and adipocytokines that 
antagonize PPARγ activity, leading to decreased adipogenesis or delipidation. 
CLA regulation of apoptosis 
CLA induces (pre)adipocyte apoptosis.  Apoptosis is another mechanism by which CLA 
may reduce BFM.  Apoptosis can occur through activation of the death receptor pathway, 
endoplasmic reticulum (ER) stress, or the mitochondrial pathway (Fig. 8).  In rat 
mammary cancer cells, a 16-128 μM CLA mixture prevented rat mammary cancer cell 
growth through apoptosis and decreased DNA synthesis (IP et al. 1999).  A number of in 
vivo and in vitro studies have reported apoptosis in adipocytes supplemented with a CLA 
mixture or 10,12 CLA alone (Evans et al. 2000, Miner et al. 2001, Hargrave et al. 2004, 
Moon et al. 2006, LaRosa et al. 2006).  For example, supplementation of C57BL/6J mice 
with 1% (w/w) CLA mixture reduced BFM and increased apoptosis and TNFα gene 
expression in WAT (Tsuboyama-Kasaoka et al. 2000).  TNFα gene expression and 
secretion has also been reported to be increased following supplementation of mice with 
10,12 CLA alone (House et al. 2005, Poirier et al. 2006).  TNFα is a major signaling 
cytokine involved in apoptosis (Wang et al. 1996) and adipocytes function (Cawthorn et 
al. 2007).  In vitro studies have demonstrated that TNFα gene expression was acutely 
increased by 10,12 CLA, but secretion was not affected in cultures of newly 
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differentiated human adipocytes (Brown et al. 2004, Chung et al. 2005b).  Mice fed a 
high-fat diet containing 1.5% (w/w) CLA mixture had an increased ratio of BAX, an 
inducer of apoptosis relative to Bcl2, a suppressor of apoptosis (Liu et al. (2007). 
CLA may induce apoptosis by activating ER stress and the integrated stress 
response (ISR).  Microarray analysis demonstrated that treatment of mice with 1% (w/w) 
10,12 CLA  and 3T3-L1 adipocytes with 100 μmol/L 10,12 CLA increased the mRNA 
levels of genes involved in the ISR such as activating transcription factor 3 (ATF3), 
C/EBP homologous protein (CHOP), pseudokinase Tribbles 3/SKIP 3 (TRIB3), X-box 
binding protein (XBP-1), and growth arrest and DNA damage inducible protein 
(GADD34) (LaRosa et al. 2007).  CHOP is known to possess apoptotic characteristics 
and activation of this protein can lead to induction of GADD34 and TRIB3 (Ohoka et al. 
2005, Szegezdi et al. 2006).   Notably, the ISR by CLA preceded the induction of 
inflammatory genes such as IL-6 and IL-8 in adipocytes (LaRosa et al. 2007).  In 
mammary tumor cells, 10,12 CLA treatment (20-40 μM) increased CHOP expression and 
ER stress leading to apoptosis (Ou et al. 2008), further supporting CLA inducing 
apoptosis in WAT.  Collectively, these data suggest that CLA may increase apoptosis in 
WAT, thereby decreasing adipocytes number via activating ER stress and the ISR, 
depending on the dose and isomer used.  In vivo studies are needed demonstrating that 
these apoptotic effects of CLA are specific to WAT, and not found in other tissues. 
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Conclusion and Implications 
Supplementation with a mixture of CLA isomers or 10,12 CLA alone consistently 
reduces adiposity in animal models, especially in rodents, but only in some humans.  
Potential reasons for these species differences include 1) the CLA isomers used (i.e., 
10,12, but not 9,11, CLA reduces adiposity or TG content of WAT), 2) the dosage used 
(i. e., rodents consume ~20 times more CLA/kg body weight compared to human 
studies), and 3) age, body weight, body fat, or metabolic status of the animals or subjects.   
Potential mechanisms responsible for these anti-obesity properties of 10,12 CLA include 
1) decreasing energy intake by suppressing appetite (Cao et al. 2007, So et al. 2009) or 
increasing energy expenditure via activation of AMPK and UCP in WAT, muscle, and 
liver tissue (West et al. 2000, Nagao et al. 2003, Terpstra et al. 2003, House et al. 2005, 
Choi et al. 2007, Ribot et al. 2007, Close et al. 2007, Wendel et al. 2007, So et al. 2008, 
Ferramosca et al. 2008), or LBM (Bhattacharya et al. 2005, Banu et al. 2006, 2007, 
2008), 2) decreasing lipogenesis (Brown et al. 2001, Brown et al. 2003, Brown et al. 
2004, Chung et al. 2005a), or increasing lipolysis (Park et al. 1997, Chung et al. 2005a, 
LaRosa et al. 2006), 3) decreasing adipogenesis (Park et al. 1997, Evans et al. 2000, 
Brown et al. 2003, Brown et al. 2004, House et al. 2005, Xu et al. 2003, LaRosa et al. 
2006, Martin et al. 2008, Kennedy 2008, Platt et al. 2008) or increasing delipidation 
(Kang et al. 2003, Brown et al. 2004, LaRosa et al. 2006, Kennedy et al. 2009), or 4) 
increasing adipocyte stress, inflammation, and/or insulin resistance (Riseruet al. al. 
2002a,b, Moloney et al. 2004, Chung et al. 2005a,b, Poirier et al. 2006,  LaRosa et al. 
2006, LaRosa et al. 2007, Kennedy et al. 2009), leading to apoptosis (Evans et al. 2000, 
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Miner et al. 2001, Tsuboyama-Kasaoka et al. 2000, Moons et al. 2006, LaRosa et al. 
2006, LaRosa et al. 2007, Lui et al. 2007).  
Based on these data, we propose the following working model (Fig. 9) depicting 
how CLA decreases WAT mass.  We speculate that 10,12 CLA either binds to a cell 
surface FA or G protein coupled receptor or passively diffuses into the adipocyte, 
activating a stress signal that increases intracellular calcium ([Ca2+]i) and reactive oxygen 
species (ROS), which in turn activates NFκB and MAPKs and increase FFA, PG, and 
adipocytokine release that together antagonize PPARγ activity, leading to insulin 
resistance, delipidation, and possibly apoptosis.  These events result in ectopic FFA 
accumulation in blood, liver, and muscle, thereby enhancing FFA availability for 
oxidation at the expense of causing FFA-induced insulin resistance in these tissues. In the 
absence of enhancing energy expenditure to oxidize these elevated levels of FFAs, 
hyperlipidemia, hyperglycemia, and lipodystrophy, ensue.  Future studies are needed to 
identify these potential upstream candidates activated by CLA that may cause this 
proposed stress cascade in adipocytes.  Elucidating this potential mechanism will provide 
valuable information on the efficacy, specificity, and potential side effects of CLA 
isomers as dietary strategies for weight loss or maintenance.  Lack of such knowledge is 
an important problem, because until it becomes available, the effective and safe use of 
CLA supplements to control obesity cannot be recommended. 
Chapters III-V will address the central hypothesis for this research that 10,12 
CLA elevates the levels of [Ca2+]i and ROS,  which lead to the activation of 
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calcium/calmodulin-dependent protein kinase II (CAMKII), MEK/ERK, and NFκB-
induced inflammation, resulting in the suppression of PPARγ activity and target gene 
expression, insulin resistance, and delipidation in primary cultures of human adipocytes.      
To test this hypothesis, the following three specific aims were investigated using 
primary cultures of newly differentiated human adipocytes. 
1. Determine the mechanism by which 10,12 CLA suppresses the expression of 
PPARγ and its target genes (Chapter III).   
2. Identify upstream mechanism(s) by which 10,12 CLA induces inflammation, 
and insulin resistance (Chapter IV).     
3. Determine the extent to which resveratrol prevents 10,12 CLA induced 
cellular stress, inflammation, insulin resistance and delipidation (Chapter V). 
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Figure 2.1 10,12 CLA regulation of energy balance.   
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Figure 2.2.  10,12 CLA increases energy expenditure. 
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Figure 2.3.  10,12 CLA inhibits adipogenesis. 
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Figure 2.4.  10,12 CLA suppresses lipogenesis. 
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Figure 2.5.  10,12 CLA inhibits insulin signaling. 
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Figure 2.6.  10,12 CLA stimulates lipolysis. 
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Figure 2.7.  10,12 CLA increases inflammation. 
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Figure 2.8.  10,12 CLA induces apoptosis. 
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Figure 2.9.  Working Model-10,12 CLA mechanism of action in adipocytes. 
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CHAPTER III 
 
 
TRANS-10, CIS-12 CONJUGATED LINOLEIC ACID ANTAGONIZES LIGAND 
-DEPENDENT PPARγ ACTIVITY IN PRIMARY CULTURES OF HUMAN 
ADIPOCYTES
 
 
 
The following chapter was previously published in the Journal of Nutrition 
volume 138, pages 455 to 461, in 2008.  The coauthors of the article were Soonkyu 
Chung, Kathy LaPoint, Oluwatoyin Fabiyi, and Michael McIntosh.  Permission from the 
publisher to use the article in its entirety can be found in Appendix A.  References from 
this article can be found in the Reference section. 
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Abstract 
We previously demonstrated that trans-10, cis-12 (10,12) conjugated linoleic acid 
(CLA) causes human adipocyte delipidation, insulin resistance, and inflammation in part 
by attenuating peroxisome proliferator activated receptor (PPAR) γ target gene 
expression.  We hypothesized that CLA antagonizes the activity of PPARγ in an isomer-
specific manner.  10,12 CLA, but not cis-9, trans-11 (9,11) CLA, suppressed ligand-
stimulated activation of a peroxisome proliferator response element (PPRE)-luciferase 
reporter. This decrease in activation of PPARγ by 10,12 CLA was accompanied by an 
increase in PPARγ and extracellular-signal related kinase (ERK)1/2 phosphorylation, 
followed by decreased PPARγ protein levels.  To investigate if 10,12 CLA-mediated 
delipidation was preventable with a PPARγ ligand (BRL), cultures were treated for 1 wk 
with 10,12 CLA or 10,12 CLA + BRL and adipogenic gene and protein expression, 
glucose uptake, and triglyceride (TG) were measured.  BRL co-supplementation 
completely prevented 10,12 CLA suppression of adipocyte fatty acid binding protein 
(aP2), lipoprotein lipase (LPL), and perilipin mRNA levels without preventing reductions 
in PPARγ or insulin-dependent glucose transporter 4 (GLUT4) expression, glucose 
uptake, or TG. Lastly, the impact of CLA withdrawal in the absence or presence of BRL 
for 2 wk was investigated.  CLA withdrawal did not rescue CLA-mediated reductions in 
adipogenic gene and protein expression.   In contrast, BRL supplementation for 2 wk 
following CLA withdrawal rescued mRNA levels of PPARγ target genes.  However, the 
levels of PPARγ and GLUT4 protein and TG were only partially rescued by BRL.  
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Collectively, we demonstrate for the first time that 10,12 CLA antagonizes ligand-
dependent PPARγ activity, possibly via PPARγ phosphorylation by ERK.   
 
Introduction 
 
Dysfunction of adipose tissue can result in insulin resistance and lipodystrophy.  
One major regulator in the development and function of adipose tissue is peroxisome 
proliferation-activated receptor (PPAR)γ, which induces the expression of a host of 
adipogenic genes such as lipoprotein lipase (LPL), insulin-stimulated glucose transporter 
4 (GLUT4), perilipin (PLIN), and adipocyte fatty acid binding protein (aP2). Mutations 
of PPARγ in humans are associated with insulin resistance and lipodystrophy (Barroso et 
al. 1999, Savage et al. 2003).  PPARγ null cells exhibit impaired adipogenesis (Rosen et 
al. 1999) and dominant negative mutations in PPARγ inhibit adipogenesis (Gurnell et al. 
2000).  Thus, PPARγ activity is essential in adipose tissue for glucose uptake and TG 
accumulation. 
Regulation of PPARγ occurs through a variety of proposed mechanisms including 
1) covalent modification by phosphorylation, 2) ligand binding, and 3) 
heterodimerization with the retinoic acid receptor (RXR) (Mandrup et al. 1997, Hamm et 
al. 1999).  Phosphorylation of PPARγ by activation of the mitogen-activated-protein 
kinase (MAPK) pathway has been reported to inhibit adipogenesis (Diradourian et al. 
2005).  It has been demonstrated that phosphorylation of serine 112 of PPARγ2 results in 
its ubiquination and proteosome degradation (Hu et al. 1996).  Activation of PPARγ by 
natural (i.e., polyunsaturated fatty acids, PUFAs) or synthetic ligands such as 
38 
Thiazolidinediones (TZDs) initiates heterodimerization with RXR followed by their 
binding to PPREs in the promoters of adipogenic target genes.  The TZDs are 
hypoglycemics that activate PPARγ, leading to upregulation of adipogenic genes, thereby 
enhancing insulin sensitivity. Natural ligands of PPARγ2 such as cis- PUFAs or 
prostaglandins (PG)s such as PGJ2 (Shiraki et al. 2006) have a relatively low affinity for 
PPARγ compared to TZDs.  In contrast, saturated fatty acids and certain trans PUFAs 
such as conjugated linoleic acid (CLA) have been reported to impair insulin sensitivity, 
possibly by decreasing the expression of PPARγ and many of its downstream target 
genes (Brown et al. 2003, Brown et al. 2004, Kang et al. 2003, Granlund et al. 2003). 
CLA consists of dienoic isomers of linoleic acid, including trans-10, cis-12 CLA 
and cis-9, trans-11 CLA.  CLA decreases body fat mass in animals (House et al. 2005) 
and some humans (Larsen et al. 2003).  Our group has demonstrated that trans-10, cis-12 
CLA decreases adipogenic gene expression and the triglyceride (TG) content of human 
(pre)adipocytes (Brown et al. 2003, Brown et al. 2004).  We have also demonstrated that 
activation of mitogen-activated protein kinase kinase/extracellular signal-related kinase 
(MEK/ERK) (Brown et al. 2004) and nuclear factor κB (NFκB) (Chung et al. 2005) 
signaling by trans-10, cis-12 CLA were essential for its suppression of adipogenic gene 
expression and delipidation in human adipocytes.  A number of side effects have been 
associated with trans-10, cis-12 CLA supplementation in humans such as insulin 
resistance, hyperglycemia, and dyslipidemia (Riserus et al. 2002, Riserus et al. 2004).  
Dyslipidemia, insulin resistance, and hyperglycemia are similar characteristics found in 
humans with mutations in PPARγ.  Two recent reports by Belury’s group (Lui et al. 
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2007, Purushotham et al. 2007) show that the PPARγ agonist Rosiglitazone prevents or 
attenuates inflammation, lipodystrophy, and insulin resistance in mice fed a crude 
mixture of CLA isomers containing equal amounts of cis-9, trans-11 CLA and trans-10, 
cis-12 CLA. However, the isomer-specific mechanism by which CLA suppresses the 
expression of PPARγ and its target genes in human adipocytes remains to be elucidated.  
To address this issue, we examined the impact of CLA on PPARγ in the absence and 
presence of the PPARγ  ligand Rosiglitazone (BRL).   
 
Materials and Methods 
Materials 
All cell culture ware were purchased from Fisher Scientific (Norcross, GA). 
Western lightning chemiluminescence substrate was purchased from Perkin Elmer Life 
Science (Boston, MA).  One-step reverse transcription-polymerase chain reaction (RT-
PCR) kit used in semi-quantitative mRNA analysis was purchased from Qiagen, Inc 
(Valencia, CA). Immunoblotting buffers, precast gels and gene-specific primers were 
purchased from Invitrogen (Carlsbad, CA), and ribosomal 18S competimer technology 
internal standards and DNA-free were purchased from Ambion (Austin, TX).  Polyclonal 
GLUT4 antibody was a gift from Drs. S. Cushman and X. Chen (NIDDK, NIH, 
Bethesda, MD). aP2 antibody was a gift from Dr. D. Bernlohr (University of Minnesota). 
Monoclonal antibodies for PPARγ (sc7273) and polyclonal antibodies for anti-
glyceraldehydre-3-phosphate dehydrogenase (GAPDH) (sc20357) and β-actin (sc1616) 
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phospho (Thr-
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202/204) and total ERK antibodies were purchased from Cell Signaling Technologies 
(Beverly, MA).  Cy3- and FITC-conjugated IgG were purchased from Jackson 
Immunoresearch (West Grove, PA). Fetal bovine serum (FBS) was purchased from 
Cambrex/BioWhittaker (Walkersville, MD).  BRL was a gift from Glaxo Smith Kline.  
Isomers of CLA (+98% pure) were purchased from Matreya (Pleasant Gap, PA). The 
Nucleofactor and Dual Glo luciferase kits were obtained from Amaxa (Cologne, 
Germany) and Promega (Madison, WI), respectively. All other reagents and chemicals 
were purchased from Sigma Chemical (St. Louis, MO) unless otherwise stated. 
 
Culturing of human primary adipocytes 
Abdominal white adipose tissue (WAT) was obtained from non-diabetic females, 
between the ages of 20-50 years old with a body mass index (BMI) ≤ 30 during 
abdominoplasty with consent from the Institutional Review Board at the University of 
North Carolina at Greensboro. Tissue was digested using collagenase and stromal 
vascular (SV) cells were isolated as previously described (Brown et al. 2004). 
Experimental treatment of cultures containing ~50% preadipocytes and ~50% adipocytes 
occurred on day 12 of differentiation. Each experiment was done in duplicate and 
repeated at least three times using a mixture of cells from 2-3 subjects unless otherwise 
indicated.   
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Preparation of fatty acids 
Both isomers of CLA were complexed to fatty acid-free (>98%) bovine serum 
albumin (BSA) at a 4:1 molar ratio using 1 mmol/L BSA stocks. 
 
Immunoblotting 
Immunoblotting was conducted as we previously described (Brown et al. 2004). 
To resolve PPARγ phospho-proteins, total cell extracts (75 ug protein) were subjected to 
10% SDS-PAGE (acrylamide:bisacrylamide 100:1 w/w) containing 4 M urea and to 
electrophoresis at 80 V for 20 h as we previously described (Chung et al. 2006). 
Separated proteins were subsequently transferred to PVDF membranes and 
immunoblotted with a monoclonal PPARγ antibody.  For determining the 
phosphorylation status of PPARγ, a portion of the cell extracts from BSA vehicle and 
CLA treatment were incubated with 20 U of calf intestinal phosphatase (Cip) for 30 min 
at 37°C and for 15 min at 55°C.  Subsequently, the samples were subjected to SDS-
PAGE containing urea as described above. 
 
Immunostaining of PPARγ 
Cells were cultured on coverslips for immunofluorescence microscopy and 
stained as described previously (Brown et al. 2004) except for the permeablization step. 
Fixed cells were permeabilized with 0.1% Triton X-100 for 1 min on ice. Monoclonal 
anti-PPARγ (1:10) were incubated overnight at 4ºC. Fluorescent images were captured 
with a SPOT digital camera mounted on an Olympus BX60 fluorescence microscope. 
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Transient transfections of human adipocytes 
For measuring PPARγ activity, primary human adipocytes were transiently 
transfected with the multimerized PPAR-responsive luciferase (luc) reporter construct 
pTK-PPRE3x-luc (Kliewer et al. 1992) using the Amaxa Nucleofactor as previously 
described (Chung et al. 2006). On day 6 of differentiation, 1 x 106 cells from a 60 mm 
plate were trypsinized and resuspended in 100 µL of nucleofector solution (Amaxa) and 
mixed with 2 µg of pTK-PPRE3x-luc and 25 ng pRL-CMV for each sample. 
Electroporation was performed using the V-33 nucleofector program (Amaxa). Cells 
were replated in 96-well plates after 10 min recovery in calcium-free RPMI media. 
Firefly luciferase activity was measured using the Dual-Glo luciferase kit and normalized 
to Renilla luciferase activity from the co-transfected control pRL-CMV vector. All 
luciferase data are presented as a ratio of firefly luciferase to Renilla luciferase activity.  
We consistently obtained ~75% transfection efficiency revealed by parallel transfections 
with a green fluorescent protein reporter construct. Both adipocytes and non-adipocytes 
were transfectable using this protocol based on aP2 immunostaining and DAPI nuclear 
staining. 
 
RNA analysis 
Following treatment, cultures were harvested for total RNA using Tri-Reagent 
according to manufacturer’s protocol.  Contaminating DNA was removed with DNAase 
(DNA-free, Ambion).  1 ug of RNA from each sample were used for semi-quantitative 
RT-PCR using the One-Step RT-PCR kit (Qiagen) as previously described in (Brown et 
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al. 2003).  The gene specific primer pairs used were previously described (Brown et al. 
2003). 
 
Lipid staining 
Lipid staining of cultures of human adipocytes was conducted as previously 
described (Brown et al. 2003) using Oil-Red-O (ORO). 
 
 [3H] 2-deoxy-glucose uptake  
Newly-differentiated cultures of adipocytes were incubated with BSA vehicle, 30 
umol/L cis-9, trans-11 CLA, 30 umol/L trans-10, cis-12 CLA, 30 umol/L trans-10, cis-12 
CLA + 1 umol/L BRL, or 1 umol/L BRL in adipocyte media for 2 d.  Then, for an 
additional 2 d, cultures were incubated in 1 ml of serum-free basal DMEM containing 
1,000 mg/liter D-(+)-glucose with or without 20 pmol/L of human insulin with BSA 
vehicle, 30 umol/L cis-9, trans-11 CLA, 30 umol/L trans-10, cis-12 CLA,  30 umol/L 
trans-10, cis-12 CLA + 1 umol/L BRL, or 1 umol/L BRL in adipocyte media for another 
2 d.  Following the experimental treatments, insulin-stimulated uptake of [3H]-2-deoxy-
glucose was measured following a 90 min incubation in the presence of 100 nmol/L 
human insulin as described previously (Chung et al. 2005). 
 
Statistical analysis   
Statistical analyses were performed for data in Figure 3.1 testing the main effects 
of BRL and CLA and the interaction of the two (BRL x CLA) using two-way ANOVA 
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(JMP Version 6.03, SAS Institute; Cary, NC).  Analyses for statistically significant 
differences for data in Figure 3.4C were conducted using one-way ANOVA.  Student’s t 
tests were used to compute individual pairwise comparisons of least square means 
(P<0.05).  Data are expressed as the means ± S.E.    
 
Results 
Trans-10, cis-12 CLA decreases the activity and increases phosphorylation of 
PPARγ.  
To determine the extent to which CLA decreased PPARγ activity, basal and 
ligand-induced activation of PPARγ activity were examined. There were no significant 
differences in basal levels of PPARγ activity due to CLA treatment in the absence of 
BRL (Fig. 3.1).  However, PPARγ activity in BRL-stimulated cultures (+BRL) was lower 
in cultures treated with 30 umol/L trans-10, cis-12 CLA compared to control and 30 
umol/L cis-9, trans-11 CLA-treated cultures. The extent to which trans-10, cis-12 CLA 
decreased PPARγ activity (~40%) was comparable to that of PPARγ antagonist GW9662, 
which inhibited ligand-induced PPARγ activity without impacting basal activity (data not 
shown). 
Given the inverse relationship between PPARγ activity and its phosphorylation 
status (Diradourian et al. 2005), we wanted to determine the kinetics of PPARγ 
phosphorylation during treatment with trans-10, cis-12 CLA. Trans-10, cis-12 CLA 
caused a band shift in PPARγ1/2 after 24 h treatment (Fig. 3.2A). Intriguingly, robust 
ERK1/2 phosphorylation at 24 h accompanied the PPARγ1/2 band shift, consistent with 
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ERK1/2’s role as a donor of phosphate groups to nuclear PPARγ1/2, and with our 
published data demonstrating that ERK1/2 is required for CLA’s suppression of 
adipogenic gene expression and glucose uptake (Brown et al. 2004).  However, because a 
PPARγ band shift could be due to processes other than phosphorylation (e.g., by 
acetylation, methylation, or sumylation), calf intestinal alkaline phosphatase (Cip) was 
added to the cell extracts to remove phosphorylated groups.  Trans-10, cis-12 CLA-
induced band shifts of PPARγ1/2 were either lowered or attenuated by phosphatase 
treatment (Fig. 3.2B).  Taken together, these data suggest that trans-10, cis-12 CLA 
promotes PPARγ and ERK phosphorylation, which contributes, at least in part, to CLA’s 
isomer-specific reduction of PPARγ activity.  
 
Trans-10, cis-12 CLA decreases the protein levels of PPARγ.   
We previously demonstrated that a physiological level (e.g., 30 umol/L) of trans-
10, cis-12 CLA decreased the mRNA levels of PPARγ and several of its target genes in 
differentiating cultures of human SV cells (Brown et al. 2003), and in the newly-
differentiated cultures of human adipocytes (Brown et al. 2004). However, the isomer-
specific impact of CLA on PPARγ protein levels in human adipocytes is unknown.  
PPARγ2 protein levels were decreased after 4 d and undetectable after 6 d of treatment 
with trans-10, cis-12 CLA compared to the BSA vehicle or cis-9, trans-11 CLA-treated 
cultures (Fig. 3.3A).  Consistent with these data, newly-differentiated cultures treated 
with 30 umol/L trans-10, cis-12 CLA for 4 d had dramatically less nuclear PPARγ 
staining compared to BSA vehicle-treated cultures (Fig. 3.3B).  These data demonstrate 
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that trans-10, cis-12 CLA decreases PPARγ protein levels in an isomer-specific manner 
in newly-differentiated human adipocytes.  
 
Chronic effects of a trans-10, cis-12 CLA in the presence of a PPARγ ligand. 
To further evaluate the antagonistic effects of trans-10, cis-12 CLA on PPARγ 
activity, we examined the extent to which co-supplementation with the PPARγ agonist 
BRL could prevent trans-10, cis-12 CLA suppression of adipogenic genes and proteins, 
glucose uptake, and TG accumulation.  Trans-10, cis-12 CLA decreased the mRNA (Fig. 
3.4A) and protein (Fig. 3.4B) levels of PPARγ, aP2, LPL, and GLUT4 compared to BSA 
vehicle controls or cis-9, trans-11 CLA.  Although BRL co-supplementation prevented 
CLA-mediated reductions in aP2, LPL, and PLIN gene expression, it did not prevent 
CLA suppression of PPARγ2 or GLUT4 mRNA levels (Fig. 3.4A).  Consistent with these 
data, BRL co-supplementation prevented CLA suppression of aP2 protein expression, but 
did not prevent CLA suppression of PPARγ or GLUT4 protein levels (Fig. 3.4B). 
CLA isomer-specific reduction of insulin-stimulated glucose uptake (Fig. 3.4C) or 
TG accumulation (Fig. 3.4D) was not prevented by co-supplementation with BRL.  
Collectively, these data demonstrate that trans-10, cis-12 CLA chronically suppresses 
adipogenic gene and protein expression, glucose uptake, and TG content, which are only 
partially prevented by a PPARγ ligand. 
 
Effects of withdrawal from trans-10, cis-12 CLA in presence of a PPARγ ligand. 
Next, we wanted to determine if the delipidating effects of CLA could be rescued 
by CLA withdrawal in the absence or presence of a PPARγ ligand.  Surprisingly, 
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withdrawal of trans-10, cis-12 CLA treatment for 2 wk did not restore the mRNA levels 
of LPL, PLIN, or GLUT4 gene (Group1, Fig. 3.5A) or the protein levels of PPARγ or 
GLUT4 (Group 1, Fig. 3.5B).  Interestingly, the pattern of gene and protein expression in 
Group 1 was almost identical to that of the cultures treated for 1 wk with trans-10, cis-12 
CLA (Fig. 3.4), indicating the effects of CLA were sustained over 2 wk.  Consistent with 
these gene and protein data, cultures treated with trans-10, cis-12 CLA had less stainable 
TG 2 wk after withdrawal (Group 1, Fig. 3.5C) compared to controls.   
BRL supplementation for 2 wk following CLA withdrawal rescued PPARγ, aP2, 
and LPL gene expression compared to BSA vehicle- or cis-9, trans-11 CLA-treated 
cultures, while PLIN and GLUT4 were partially rescued (Group 2, Fig. 3.5A).  BRL 
supplementation for 2 wk following CLA withdrawal reversed or attenuated trans-10, cis-
12 CLA suppression of aP2 and GLUT4 protein levels, respectively, compared to 
cultures not receiving BRL for 2 wk (Group 1).  Although CLA-treated cultures 
supplemented for 2 wk with BRL (Group 2) had more PPARγ protein compared to those 
not receiving BRL for 2 wk (Group 1), PPARγ protein levels did not return to the levels 
of the BSA vehicle- or cis-9, trans-11 CLA-treated cultures.  Similarly, supplementation 
of cultures with BRL for 2 wk during CLA withdrawal (Group 2) marginally increased 
TG content of cultures treated with trans-10, cis-12 CLA compared to cultures not 
receiving BRL during withdrawal (Group 1).  Interestingly, BRL was only effective in 
preventing delipidation when it was co-supplemented with CLA and then supplemented 
for another 2 wk following CLA withdrawal (Group 2, Fig. 3.5C).  Taken together, these 
data demonstrate that trans-10, cis-12 CLA-mediated delipidation persists after CLA 
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withdrawal, and is relatively refractory to supplementation with a PPARγ ligand unless 
the ligand is supplemented during and after CLA treatment.   
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Figure 3.1.   10,12 CLA blocks ligand-induced activation of PPARγ. Cultures of 
newly-differentiated human adipocytes were transfected on day 6 with pTK-PPRE3x-luc 
and pRL-CMV. Twenty four hours later, transfected cells were treated with DMSO 
vehicle control (C), 30 umol/L trans-10, cis-12 CLA, or 30 umol/L cis-9, trans-11 CLA in 
the absence or presence of 0.1 umol/L BRL for 24 h.   (+ SEM, n=3). 
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Figure 3.2.  10,12 CLA increases PPARγ phosphorylation.  A: Cultures of newly- 
differentiated human adipocytes were serum-starved for 24 h and then treated without (0) 
or with 30 umol/L trans-10, cis-12 CLA (10) for 2, 4, 8, or 24 h. Subsequently, cell 
extracts were harvested, proteins separated by SDS-PAGE-urea, and immunoblotted for 
the phosphorylated and unphosphorylated forms of PPARγ1/2, ERK1/2, and GAPDH 
(load control).  B: Cultures were treated for 24 h with BSA vehicle (B) or 30 umol/L 
trans-10, cis-12 CLA (10).  A portion of the cell extracts from BSA vehicle and CLA 
treatment were incubated with calf intestinal phosphatase (Cip).  Proteins were separated 
with SDS-PAGE-urea, and probed with antibodies targeting PPARγ1/2 and GAPDH.  
Data in Panels A and B are representative of 2 independent experiments. 
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Figure 3.3.  10,12 CLA decreases PPARγ protein levels.  A: Cultures of newly-
differentiated human adipocytes were treated with BSA vehicle (B), 30 umol/L cis-9, 
trans-11 CLA (9), or 30 umol/L trans-10, cis-12 CLA (10) for 2, 4, 6, or 8 d. Cells 
extracts were immunoblotted for PPARγ. To identify PPARγ1/2 in cultures of human 
adipocytes, cell extracts from 3T3-L1 adipocytes (mouse) were isolated and 
immunoblotted for PPARγ.  A third band was identified in human adipocytes and labeled 
as nonspecific (NS). B: Cultures were treated with BSA vehicle (B) or 30 umol/L trans-
10, cis-12 CLA (10) for 4 d.  PPARγ was detected using immunofluoresence microscopy.  
Data are representative of 2 independent experiments. 
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Figure 3.4.  10,12 CLA antagonizes ligand-activated PPARγ expression, glucose 
uptake, and TG accumulation.  A:  Cultures of newly-differentiated human adipocytes 
were treated for 1 wk with either BSA vehicle (B), 30 umol/L cis-9, trans-11 CLA (9), 30 
umol/L trans-10, cis-12 CLA (10), or 30 umol/L trans-10, cis-12 CLA + 1 umol/L BRL 
(10*) and then harvested. RNA was isolated and the mRNA levels of PPARγ2, 
adipocyte-specific fatty acid binding protein (aP2), lipoprotein lipase (LPL), perilipin 
(PLIN), and insulin-sensitive glucose transporter 4 (Glut 4) were measured using semi-
quantitative RT-PCR.  18S rRNA was used as an internal control.  B: Cultures were 
treated as in Panel A for 1 wk and then cell extracts were isolated and immunoblotted for 
PPARγ, aP2, Glut4, and β-actin. C: Cultures were treated as in Panel A for 4 d and then 
insulin-stimulated uptake of [3H]-2-deoxy-glucose was measured.  Means (+ SEM; n=6).  
D:  Cultures were treated as in Panel A for 1 wk and then stained with oil Red O and 
phase-contrast photomicrographs were taken using an Olympus inverted microscope with 
a 10X objective.  Data in A, B, and D are representative of 2-3 independent experiments. 
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Figure 3.5.  Effects of withdrawal of 10,12 CLA in the presence of a PPARγ ligand.  
Cultures of newly-differentiated human adipocytes were treated for 1 wk with either BSA 
vehicle (B), 30 umol/L cis-9, trans-11 CLA (9), 30 umol/L trans-10, cis-12 CLA (10), or 
30 umol/L trans-10, cis-12 CLA + 1 umol/L BRL (10*) and then had their treatments 
withdrawn for 2 wk (Group 1, -BRL), or were treated with 1umol/L BRL for 2 wk during 
CLA withdrawal (Group 2, +BRL).  A: RNA was isolated and the mRNA levels of 
PPARγ2, aP2, LPL, PLIN, and Glut4 were measured using semi-quantitative RT-PCR.  
18S rRNA was used as an internal control. B: Cell extracts were isolated and 
immunoblotted for PPARγ aP2, Glut4, and β-actin. C: Cultures were stained with Oil 
Red O and phase-contrast photomicrographs were taken using an Olympus inverted 
microscope with a 10X objective.  Data are representative of 2-3 independent 
experiments.
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Figure 3.6.  Working Model.  CLA, metabolites, or signals suppress PPARγ activity by 
1) phosphorylating PPARγ via activation of NFκB and ERK1/2, 2) inhibiting ligand 
activation and/or heterodimer formation with RXR, or 3) impairing transcriptional 
activation of target genes, thereby decreasing TG synthesis. 
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Discussion 
The PPARγ agonist Rosiglitazone has been demonstrated to prevent or attenuate 
inflammation, lipodystrophy, and insulin resistance in mice fed a crude mixture of CLA 
isomers (e.g., primarily cis-9, trans-11 CLA and trans-10, cis-12 CLA) (19, 20).  These 
data suggest an antagonism between one or both CLA isomers and PPARγ.  However, the 
isomer-specific mechanism by which CLA suppresses the activity of PPARγ in human 
adipocytes remains unknown.  We demonstrate in this article that trans-10, cis-12, but not 
cis-9, trans-11, CLA attenuates ligand-induced activation of PPARγ (Fig. 3.1), possibly 
via phosphorylation of PPARγ by ERK1/2 (Fig. 3.2).  Inactivation of PPARγ leads to 
suppression of protein and mRNA levels of PPARγ and several of its target genes in 
newly-differentiated human adipocytes (Figs. 3.3, 3.4, 3.5).  BRL co-supplementation did 
not prevent insulin resistance caused by trans-10, cis-12 CLA (Fig. 3.4).  Furthermore, 
we show that trans-10, cis-12 CLA-mediated suppression of TG accumulation does not 
return to control levels following CLA withdrawal or by supplementation with a PPARγ 
agonist following CLA treatment (Fig. 3.5).  Only BRL co-supplementation followed by 
2 wk of BRL supplementation restored the TG content of trans-10, cis-12 CLA-treated 
cultures to control levels. Taken together, these data provide further support for the 
concept that CLA’s anti-adipogenic effects in humans are 1) due to the trans-10, cis-12 
isomer and not the cis-9, trans-11 isomer, and 2) directly linked to the suppression of 
PPARγ activity, adipogenic gene and protein expression, insulin-stimulated glucose 
uptake and TG content, which appears to be due in part to an antagonism of ligand-
mediated activation of PPARγ. 
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Potential mechanisms explaining the isomer-specific attenuation of PPARγ activity 
by CLA are shown in our working model in Fig. 3.6.  We propose that trans-10, cis-12 
CLA, a metabolite, or a signal activated by CLA suppresses PPARγ activity by 1) 
phosphorylating PPARγ via activation ERK1/2, 2) inhibiting ligand activation and 
heterodimer formation with RXR, or 3) impairing DNA binding of the PPRE to target 
genes, thereby decreasing adipogenic gene transcription, insulin-stimulated glucose 
uptake, and TG synthesis.   
PPARγ phosphorylation.  Support for the first two mechanisms comes from our 
discovery that trans-10, cis-12 CLA suppresses adipogenic gene expression and 
metabolism through activation of ERK1/2 (Brown et al. 2004) and NFκB (Chung et al. 
2006).  Reports demonstrating that NFκB (Jiang et al. 2001, Ruan et al. 2002, Ruan et al. 
2003, Suzawa et al. 2003, Nie et al. 2005) and MAPK (Adams et al. 1997, Camp et al. 
1997, De Mora et al. 1997) activation hinders PPARγ DNA binding affinity or 
transcriptional activation provides a potential mechanism by which trans-10, cis-12 CLA 
suppresses the expression of PPARγ target genes, leading to delipidation.  ERK1/2 
activates NFκB (Chen et al. 2004) and inactivates PPARγ (Shao et al. 1998), resulting in 
its ubiquination and proteosome degradation (Burns et al. 2007).  Further support comes 
from studies showing that PPARγ agonists attenuate cytokine-mediated inflammation by 
suppressing NFκB and/or MAPK signaling (Su et al. 1999, Staus et al. 2000, Chen et al. 
2004, Engleman et al. 2005).  Clearly, the activity of PPARγ is regulated by its 
phosphorylation status via phosphatases and kinases (Burns et al. 2007).  Indeed, the 
phosphorylation of PPARγ at a consensus MAPK site within its A/B domain (e.g., serine 
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112) by ERK1/2 or JNK reduces its transcriptional activation potential, leading to insulin 
resistance and/or decreased adipogenesis (Hu et al. 1996, Adams et al. 1997, Camp et al. 
1997, De Mora et al. 1997, Shao et al. 1998, Engleman et al. 2005, Zhang et al. 1996).  
Interestingly, we previously reported that the MEK/ERK inhibitor U0126 blocked trans-
10, cis-12 CLA suppression of adipogenic genes and glucose and fatty acid uptake 
(Brown et al. 2004).  Consistent with these data, we found that trans-10, cis-12 CLA 
simultaneously increased the phosphorylation of ERK1/2 and PPARγ (Fig. 3.2A).   Based 
on these data, our working hypothesis is that trans-10, cis-12 CLA antagonizes PPARγ’s 
activity acutely and PPARγ expression chronically in adipocytes via NFκB and ERK1/2 
activation, leading to decreased glucose and fatty acid uptake and TG synthesis.  
Ligand binding. CLA may also compete with endogenous (i.e., unsaturated fatty 
acids) or exogenous (i.e., Rosiglitazone-BRL) ligands for activation of PPARγ.  Low 
affinity PPARγ ligands such as PUFAs increase PPARγ activity and target gene 
expression (Kahn et al. 2003).  Several CLA isomers, including cis-9, trans-11 CLA, 
have been shown to be ligands for PPARγ (Granlund et al. 2003, Yu et al. 2002) or its 
partner RXR (Kahn et al. 2003).  Consistent with the reported antagonism between 
PPARγ and inflammation, cis-9, trans-11 CLA has been shown to suppress NFκB 
activation and inflammatory cytokine production by lipopolysaccharide (LPS) in 
dendritic cells (Loscher et al. 2005) and in WAT of obese mice (Moloney et al. 2007).   
However, we found that co-supplementation of trans-10, cis-12 CLA-treated cultures 
with up to 30 umol/L cis-9, trans-11 CLA did not reverse insulin resistance or adipogenic 
gene expression (data not shown).  In contrast, Granlund et al. 2003 demonstrated that 
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both cis-9, trans-11 CLA and trans-10, cis-12 CLA decreased the activity of a 
Darglitazone-stimulated, LXRα-PPRE-LUC reporter in a dose-dependent manner up to 
25 umol/L in COS-1 cells and 3T3-L1 cells (Granlund et al. 2003).  We have also 
demonstrated in 3T3-L1 that both CLA isomers antagonize ligand-induced activation of 
PPARγ (Brown et al. 2003).   Alternatively, CLA phosphorylation of PPARγ in the A/B 
domain could reduce PPARγ affinity for ligand and/or cofactor recruitment (Burns et al. 
2007). 
Transcriptional activation.  Another possible mechanism by which CLA reduces 
PPARγ activity is by impairing DNA binding of the PPARγ/RXR heterodimer itself to 
the PPRE in target genes, thereby decreasing transcriptional activation.  Conceptually, 
this would lead to decreased lipogenesis and TG accumulation.  However, chromatin 
immunoprecipation studies are needed to support this speculative mode of action of CLA.   
One possible explanation for the long-term effects of CLA following withdrawal 
could be that CLA accumulates within the phospholipid and neutral lipid fractions of the 
cell, as we have previously shown for both isomers (Brown et al. 2003). Thus, CLA 
could continue to antagonize PPARγ/RXR activity following withdrawal, thereby 
impacting endogenous ligand production, phosphorylation, and/or directly interfering 
with their transcriptional activation.   
In summary, although co-supplementation with BRL, a high affinity ligand for 
PPARγ, generally prevented or attenuated trans-10, cis-12 CLA suppression of 
adipogenic gene and protein expression and TG content, it did not prevent CLA’s 
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suppression of a PPARγ reporter construct or insulin-stimulated glucose uptake.  
Furthermore, BRL supplementation for 2 wk after CLA withdrawal did not completely 
rescue its anti-adipogenic and TG-lowering effects.  Taken together, these data suggest 
that trans-10, cis-12 CLA may decrease PPARγ activity acutely by increasing PPARγ 
phosphorylation via ERK1/2 and chronically by decreasing PPARγ transcription, thereby 
decreasing the amount PPARγ available for ligand binding, leading to the suppression of 
insulin-stimulated glucose uptake and TG accumulation.  
 
60 
CHAPTER IV 
 
 
INFLAMMATION AND INSULIN RESISTANCE INDUCED BY TRANS-10, CIS-
12 CONJUGATED LINOLEIC ACID ARE DEPENDENT ON INTRACELLULAR 
CALCIUM LEVELS IN PRIMARY CULTURES OF HUMAN ADIPOCYTES
 
 
 
Abstract 
We previously demonstrated that trans-10, cis-12 (10,12) conjugated linoleic acid 
(CLA) caused inflammation and insulin resistance in cultures of human adipocytes by 
activating nuclear factor κB (NFκB) and extracellular signal related kinase (ERK) 
signaling. However, the upstream mechanism by which CLA activates ERK and NFκB is 
unclear.  In this study, we tested the hypothesis that intracellular calcium [Ca2+]i is an 
upstream mediator of this effect.  We demonstrated that the increase in [Ca2+]i mediated 
by 10,12 CLA was attenuated by BAPTA, an intracellular calcium chelator, and by 
TMB-8, a chemical inhibitor of calcium release from endoplasmic reticulum (ER), and 
D609, a phospholipase C (PLC) inhibitor, but not by the extracellular calcium chelator 
EGTA.  These data suggest that 10,12 CLA increases [Ca2+]i levels by stimulating 
calcium release from the ER. Moreover, BAPTA, TMB-8, and D609 also attenuated 
10,12 CLA-mediated production of reactive oxygen species (ROS), activation of ERK1/2 
and cJun-NH2-terminal kinase (JNK), or induction of inflammatory and stress response 
gene expression. Consistent with these data, 10,12 CLA-mediated binding of NFκB to the 
promoters of interleukin (IL)-8 and cyclooxygenase (COX)-2 was attenuated by TMB-8. 
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KN-62, a calcium-calmodulin kinase (CaMK) inhibitor, also suppressed 10,12 CLA-
mediated ROS production and ERK1/2 and JNK activation.  Additionally, KN-62 
attenuated 10,12 CLA induction of inflammatory and stress response genes, increase in 
prostaglandin F2α, and suppression of peroxisome proliferator activated receptor gamma 
protein levels and insulin-stimulated glucose uptake. Collectively, these data suggest that 
10,12 CLA-mediated ROS production, MAPK activation, inflammatory gene induction 
and insulin resistance are dependent on calcium release from the ER or CaMK activity in 
human adipocytes.  
 
Introduction 
Obesity and its co-morbidities are the most prevalent metabolic diseases in the 
U.S., affecting over 30% of the adult population (CDC 2007).  Conjugated linoleic acid 
(CLA), dienoic isomers of linoleic acid, is one potential treatment for obesity.  Numerous 
animal (House et al. 2005) and human studies (Whigham et al. 2007) have demonstrated 
that supplementation with trans-10, cis-12 (10,12) CLA alone, or in a mixture with the 
cis-9, trans-11 (9,11) isomer, reduces body weight and fat deposition. 10,12 CLA has 
been shown to suppress the mRNA and protein levels of peroxisome proliferator 
activated receptor gamma (PPARγ, the master regulator of adipogenesis, in murine 3T3-
L1 adipocytes (Granlund et al. 2003) and cultures of newly-differentiated human 
adipocytes (Brown et al. 2004). 
 Our research group has reported that 10,12 CLA, but not 9,11 CLA, inhibited 
human preadipocyte differentiation (Brown et al. 2003) and caused delipidation of newly-
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differentiated human adipocytes (Brown et al. 2004). Isomer-specific delipidation of 
adipocytes by CLA was due largely to a decrease in adipogenic/lipogenic gene 
expression, uptake of glucose and fatty acids, and triglyceride (TG) synthesis as opposed 
to an increase in oxidation (Brown et al. 2004, Chung et al. 2005).  Interestingly, 10,12 
CLA suppression of glucose and fatty acid uptake was dependent on activation of 
mitogen-activated protein kinase/extracellular kinase signal-regulated kinase 
(MEK/ERK) and nuclear factor κB (NFκB) signaling, as well as robust secretion or 
expression of the proinflammatory cytokines interleukin (IL)-6, IL-8, and tumor necrosis 
factor (TNF)α (Brown et al. 2004, Chung et al. 2005, Chung et al. 2005).  Consistent with 
these in vitro data, CLA supplementation in humans is associated with hyperglycemia, 
dyslipidemia, insulin resistance, and elevated levels of inflammatory prostaglandin (PG)s 
and cytokines (Basu et al. 2003, Riserus et al. 2002, Riserus et al. 2002, Tholstrup et al. 
2007).   However, the upstream mechanism(s) by which 10,12 CLA induces 
inflammation, insulin resistance, and adipocyte delipidation remain unclear.     
One possible upstream mediator of CLA-induced inflammation and insulin 
resistance is intracellular calcium ([Ca2+]i).  [Ca2+]i  is a vital second messenger for the 
activation of proteins involved in adipocyte proliferation, differentiation, and metabolism 
(Zemel et al. 1998).  Elevated levels of [Ca2+]i have been reported to activate NFκB 
(Martin et al. 2006, Jeong et al. 2005, Gewirtz et al. 2000), ERK1/2 (Martin et al. 2006, 
Jeong et al. 2005, Melien et al. 2002), and phospholipase A2 (PLA2) (Balsinde et al. 
1999, Qui et al. 1993), leading to cytokine or PG production.  Calmodulin (CaM), a 
major calcium-dependent protein, plays an important role in inflammation and 
63 
metabolism.  CaM activates a number of protein kinases, such as CaMK I, II, and IV 
(Means et al. 2000, Colomer et al. 2007).  Relevant to this study, CaMK II has been 
shown to inhibit adipocyte differentiation in response to inflammatory PGs such as 
PGF2α (Miller et al. 1996).   
 Based on its critical role in cell signaling, enzyme activation, and adipocyte 
differentiation, we hypothesized that [Ca2+]i is an upstream mediator of 10,12 CLA-
induced inflammation and insulin resistance in human adipocytes.  In this study, we 
demonstrated for the first time that CLA increases [Ca2+]i levels, leading to the 
production of reactive oxygen species (ROS), NFκB, cJun-NH2-terminal kinase (JNK), 
ERK1/2, and ultimately, the induction of inflammatory genes and PGs, and insulin 
resistance in human adipocytes.   
 
Materials and Methods 
Materials 
All cell culture ware were purchased from Fisher Scientific (Norcross, GA). 
Lightning Chemiluminescence Substrate was purchased from Perkin Elmer Life Science 
(Boston, MA).  Immunoblotting buffers and precast gels were purchased from Invitrogen 
(Carlsbad, CA). The polyclonal antibody for anti-glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (sc20357) was obtained from Santa Cruz Biotechnology (Santa 
Cruz, CA).  Anti-phospho (P) (Thr183/185) SAPK/JNK and anti-P (Thr-202/204) and 
total ERK1/2 antibodies were purchased from Cell Signaling Technologies (Beverly, 
MA).  Hyclone fetal bovine serum (FBS) was purchased from Fisher Scientific. Isomers 
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of CLA (+98% pure) were purchased from Matreya (Pleasant Gap, PA). 
Dichlorofluorescein (DCF), Fluo-3 acetoxymethyl ester (Fluo-3 AM), and 1,2-bis (2-
aminophenoxy)ethane-N, N, N’, N’-tetraacetic acid (BAPTA)-AM were purchased from 
Molecular Probes (Eugene, OR). 8-(N,N-diethylamino)-octyl-3,4,5-trimethoxy-benzoate 
(TMB-8) and 1-[N,O-bis-(5-Isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-
phenylpiperazine (KN-62) were purchased from Calbiochem-EMD Biosciences, Inc (La 
Jolla, CA).  Ethylene glycol-bis(β-aminoethylester)-N,N,N’,N’-tetracetic acid (EGTA) 
was purchased from Sigma Chemical Co. (St. Louis, MO). All other reagents and 
chemicals were purchased from Sigma Chemical Co. unless otherwise stated. 
 
Culturing of human primary adipocytes 
Abdominal white adipose tissue (WAT) was obtained with consent from the 
Institutional Review Board at the University of North Carolina at Greensboro, during 
abdominoplasty of non-diabetic females between the ages of 20-50 years old with a body 
mass index ≤ 30. Tissue was digested using collagenase; stromal vascular cells were 
isolated as previously described (Brown et al. 2004). Cultures containing newly-
differentiated human adipocytes were treated on day 6 of the differentiation program. 
Each independent experiment was repeated at least twice using a mixture of cells from 2-
3 subjects, unless otherwise indicated. 
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Culturing of Human Simpson Golabi Behmel Syndrome (SGBS) cells 
SGBS cells were generously provided by Dr. Martin Wabitsch at the University 
of Ulm, Germany.  They were grown to confluence in Dulbecco’s Modified Eagle’s 
Medium/Nutrient Mixture F-12 Ham’s supplemented with 10% bovine serum, 33 uM 
biotin, 17 uM pantothenate, 100 ug/ml streptomycin and 62.5 ug/ml penicillin.  To induce 
differentiation, SGBS cells were washed repeatedly with PBS buffer and then cultured in 
serum-free medium supplemented with 10 nM insulin, 200 pM triiodothyronine, 1 uM 
cortisol, 2 uM BRL 49653, 0.115 mg/ml 1-methyl-3-isobutylxanthine (IBMX), 0.25 
mmol/L dexamethasone (DEX) and 0.01 mg/ml human transferrin for 4 d.  After 4 d, the 
medium was replaced with the differentiation medium lacking BRL 49653, IBMX, and 
DEX.  These cells were used for the ChIP experiments on day 6 of differentiation.    
     
Measuring ROS 
For the DCF assay, primary human adipocytes were seeded in 96-well plates and 
differentiated for 6 d.  On day 6, medium was changed to serum- and phenol red-free 
medium for 24 h.  After 24 h, cells were preloaded with 5 uM DCF 37° C for 1 h and 
then treated with various treatments for 3 h.  Cells were then washed once with HBSS 
and fluorescence was immediately measured in a plate reader with an excitation/emission 
wavelength of 485/528 nm.  DCF values were calculated after normalizing background 
fluorescence levels of DCF. 
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Measuring [Ca2+]i levels   
[Ca2+]i levels were measured using Fluo-3 AM. Briefly, cells were preloaded with 
5 uM Fluo-3 AM and an anionic detergent, 10% Pluronic F-127, at 25˚C for 30 min in 
the dark.  Cells were then washed with a buffer consisting of HBSS, CaCl2, and 
probenecid, which prevents Fluo-3 AM leakage from cells. Baseline fluorescence was 
measured using a Synergy Multi-detection Microplate Reader (Bio-Tek Inc, Winooski, 
VT).  Cells were then treated in the absence or presence of CLA isomers and ionomycin.  
Fluorescence was monitored at 10 sec intervals for 5 min. Excitation wavelength was 485 
nm and fluorescence was collected at 528 nm. Changes in the ratio of calcium-dependent 
fluorescence to prestimulus background fluorescence (F/F0) were plotted over time.  For 
simplicity, single representative experiments are shown.   
 
Immunoblotting 
Immunoblotting was performed using 4-12% NuPage precasted gels (Invitrogen) 
as previously described (Chung et al. 2005). 
 
Chromatin Immunoprecipitation (ChIP) assay 
ChIP experiments were performed essentially as described previously (Nielsen et 
al. 2006). Briefly, SGBS cells were grown and differentiated on 10 cm NUNC dishes and 
treated with BSA, CLA, or TMB. After treatment, cells were crosslinked, harvested in 
lysis buffer (i.e., 0.1% SDS, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 20 mM Tris 
pH 8.0, and 1x Complete proteinase inhibitor cocktail), sonicated, and DNA 
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concentration was determined by A260 measurement. Samples were diluted to equal 
concentrations and preincubated for 3 h with 2 µg p65 antibody (sc-372 Santa Cruz) and 
40 µg BSA in a total volume of 400 µl lysis buffer. 20 µl Protein A beads were washed 3 
times in lysis buffer, diluted in lysis buffer to a total volume of 100 µl, and incubated for 
2 h with 10 µg BSA. Following preincubation, prepared beads were added to the 
chromatin samples and incubated overnight. Beads were washed as previously described 
and DNA was purified by phenol-chloroform extraction. Immunoprecipitated DNA and 
5% input DNA were analyzed using real-time PCR.  
 
RNA isolation and PCR   
Total RNA was isolated from the cultures using Tri Reagent purchased from 
Molecular Research Center (Cincinnati, OH), according to manufacturer’s protocol.  For 
real time PCR, 2.0 ug total RNA was converted into first strand cDNA using Applied 
Biosystems High-Capacity cDNA Archive Kit (Foster City, CA).  Real time PCR was 
performed in an Applied Biosystems 7500 FAST Real Time PCR System using Taqman 
Gene Expression Assays.  To account for possible variation in cDNA input or the 
presence of PCR inhibitors, the endogenous reference gene GAPDH was simultaneously 
quantified for each sample, and these data normalized accordingly.  
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Measurement of PGF2α levels 
PGF2α levels were measured according to a standard protocol provided by 
Cayman Chemicals for their PGF2α enzyme immunoassay (EIA) kit. Medium was 
collected from cultures and assayed in duplicate at multiple dilutions.  
 
[3H]-2-Deoxy-glucose uptake   
Newly-differentiated cultures of human adipocytes were incubated in serum-free 
basal DMEM containing 1,000 mg/liter D-(+)-glucose with or without 20 pmol/L of 
human insulin. Cultures were treated with BSA vehicle, 50 uM 10,12 CLA, or 50 uM 
10,12 CLA + 10 uM KN-62 for 48 h.  Following treatment, insulin-stimulated uptake of 
[3H]-2-deoxy-glucose was measured following a 90 min incubation with 100 nmol/L 
human insulin as described previously (Brown et al. 2004). 
 
Statistical analyses 
Unless otherwise indicated, data are expressed as the means + SE Data were 
analyzed using one-way analysis of variance.   Student’s t tests were used for pairwise 
comparisons of least square means (p < 0.05).  All analyses were performed using JMP 
IN, Version 4.04 Software (SAS Institute, Cary, NC). 
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Results 
10,12 CLA increases [Ca2+]i.   
To examine the effect of CLA isomers on [Ca2+]i levels, we used the calcium-
sensitive fluorescent dye Fluo-3 AM. Ionomycin, an ionophore reported to raise [Ca2+]i 
levels by binding extracellular calcium and permeating the plasma membrane, was used 
as a positive control (Fig. 4.1).  Consistent with our hypothesis, 30 uM 10,12 CLA 
increased [Ca2+]i acutely (within sec) and chronically (over 5 min), comparable to the 
level of calcium increase in ionomycin-treated cells. In contrast, 30 uM 9,11 CLA only 
modestly increased [Ca2+]i levels.   These data demonstrate that 10,12 CLA induces an 
acute and sustained increase of [Ca2+]i levels in an isomer-specific manner, but do not 
indicate the source of [Ca2+]i  . 
 
Calcium chelators and inhibitors of calcium action block 10,12 CLA increase of 
[Ca2+]i. 
To determine the mechanism by which 10,12 CLA increased [Ca2+]i, cells were 
first treated with the [Ca2+]i chelator BAPTA-AM.  Preincubation of Fluo-3-loaded 
adipocytes with BAPTA blocked the increase of [Ca2+]i  by ionomycin (Fig. 4.2A) and 30 
uM 10,12 CLA in a dose-dependent manner (Fig. 4.2B).  
 Next, TMB-8 was used to determine the degree to which 10,12 CLA mobilized 
calcium from the ER.  As shown in Fig. 4.2C, TMB-8 attenuated the increase in [Ca2+]i 
mediated by thapsigargin, a positive control that promotes the release of calcium from the 
ER by inhibiting Ca2+-ATPase.  TMB-8 was similarly effective in attenuating 10,12 
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CLA elevation of [Ca2+]i (Fig. 4.2D), suggesting that 10,12 CLA also stimulates calcium 
release from the ER.  
Finally, cells were treated with the extracellular calcium chelator EGTA to 
determine whether 10,12 CLA induces the influx of extracellular calcium. As expected, 
EGTA suppressed ionomycin increase of [Ca2+]i (Fig. 4.2E). However, EGTA only 
slightly attenuated 10,12 CLA increase of [Ca2+]i, suggesting that extracellular calcium 
plays a minimal role in 10,12 CLA regulation of [Ca2+]i (Fig. 4.2F).  Collectively, these 
data suggest that 10,12 CLA increases [Ca2+]i to a large extent from intracellular stores, 
and in particular, by stimulating calcium release from the ER.  
 
10,12 CLA production of ROS and activation of ERK1/2 and JNK are dependent on 
[Ca2+]i  and CaMK. 
To determine the extent to which CLA production of ROS and activation of 
MAPK were dependent on [Ca2+]i, we investigated the effects of calcium chelators and 
inhibitors on ROS, ERK1/2, JNK, and ATF3 in CLA-treated cultures.  10,12 CLA (50 
uM) increased the production of ROS within 3 h in an isomer-specific manner (Fig. 4.3; 
9,11 CLA data not shown), which was blocked by BAPTA, TMB-8, and KN-62, a CaMK 
II inhibitor.   
10,12 CLA increased the phosphorylation of ERK1/2 within 12 h in an isomer-
specific manner (Fig. 4.4A), which was attenuated by BAPTA, TMB-8, and KN-62 (Fig. 
4.4A).  Phosphorylation of ERK1/2 by thapsigargin was also attenuated by TMB-8 (data 
not shown), confirming that calcium release from the ER increases ERK1/2 activation.  
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Consistent with these data, 10,12 CLA activation of JNK (Fig. 4.4B-D) was also 
attenuated by BAPTA, TMB-8, and KN-62 (Fig. 4.4D), while KN-62 and TMB-8 
attenuated 10,12 CLA’s increase of ATF3 protein levels.   These data suggest that ROS, 
ERK1/2, JNK and ATF3 are downstream targets of 10,12 CLA-mediated [Ca2+]i 
signaling and calcium-dependent CaMK.  
 
10,12 CLA regulation of NFκB is dependent on [Ca2+]i.   
To investigate the role of calcium in mediating 10,12 CLA activation of NFκB, 
cultures of human SGBS adipocytes were pretreated with 100 uM TMB-8 for 1 h and 
then treated over time (3-12 h) with 30 uM 10,12 CLA. NFκB binding to inflammatory 
genes was subsequently analyzed using ChIP.  Ten hours of treatment with 10,12 CLA 
increased NFκB binding to the IL-8 and COX-2 promoters, which was blocked by TMB-
8 (Fig. 4.5). These data suggest that 10,12 CLA induction of NFκB DNA binding to 
inflammatory genes is mediated, in part, by calcium release from the ER.  
 
10,12 CLA-mediated increase of  [Ca2+]i is linked to inflammatory gene expression.   
The integrated stress response (ISR) has been recently shown to play a role in 
10,12 CLA induction of inflammation (LaRosa et al. 2007).  To determine the effect of 
CLA on the expression of ISR and inflammatory genes, cultures were treated with 9,11 
CLA or 10,12 CLA for 6, 12, 24, or 48 h.  Both 30 uM or 100 uM 10,12 CLA increased 
the expression of ISR genes (i.e., ATF3, CHOP, GADD34) within 6-12 h (Fig. 4.6), and 
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inflammatory genes (i.e., IL-6, IL-8, IL-1β, COX-2) by 12 h (Fig. 4.7) in an isomer-
specific manner.   
To determine the importance of [Ca2+]i in mediating CLA induction of ISR and 
inflammatory genes, cultures were first pretreated with BAPTA or TMB-8, and then 
treated with 30 uM 10,12 CLA for 12 h.  BAPTA completely blocked 10,12 CLA 
induction of  IL-8, IL-6, CHOP, and GADD34 (Fig. 4.8).  BAPTA reduced COX-2 gene 
expression by 70%, while decreasing ATF3 gene expression by 44% (Fig. 4.8).  
Treatment of cultures with TMB-8 suppressed the 10,12 CLA-induced expression of IL-8, 
IL-6, COX-2, CHOP, and GADD34 (Fig. 4.8), while only modestly reducing ATF3 
mRNA levels.  To determine the role of CaMK in mediating 10,12 CLA induction of ISR 
and inflammatory genes, cultures where pretreated with KN-62. KN-62 attenuated or 
blocked induction of IL-8, IL-6, COX-2, CHOP, GADD34, and ATF3 gene expression 
(Fig. 4.8).  These data suggest that 10,12 CLA induction of ISR and inflammatory genes 
is linked to CaMK activation and the release of calcium from the ER. 
 
Phospholipase C (PLC) activity plays a role in 10,12 CLA-mediated increase in 
markers of inflammation. 
We investigated the role of PLC, a membrane-bound, signal transducing protein 
involved in the release of calcium from intracellular stores (Camina et al. 1999), using the 
PLC inhibitor D609. D609 attenuated 10,12 CLA increase of [Ca2+]i (Fig. 4.9A), ROS 
(Fig. 4.9B), and ISR and inflammatory gene expression (Fig. 4.9C). These data suggest 
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that PLC activity plays a role in 10,12 CLA mobilization of calcium, increase of ROS, 
and ISR and inflammatory gene expression.   
 
10,12 CLA activates the inflammatory PG pathway independently of [Ca2+]i.  
PGF2α has been shown to suppress adipogenesis (Miller et al. 1996), and is 
associated with inflammation and insulin resistance in humans consuming CLA 
supplements (Basu et al. 2000, Riserus et al. 2002, Riserus et al. 2002).  Consistent with 
these findings, 10,12 CLA increased COX-2 gene expression (Fig. 4.8), which was 
decreased by BAPTA, TMB-8, and KN-62. For these reasons, we hypothesized that 
[Ca2+]i plays a role in 10,12 CLA induction of the inflammatory PG pathway.  10,12 CLA 
activation of PLA2 occurred within 12 h (Fig. 4.10A) and was isomer-specific (Fig. 
4.10B).  However, neither BAPTA nor TMB-8 suppressed 10,12 CLA-mediated 
phosphorylation of PLA2 (Fig. 4.10C) or increased levels of PGF2α after 24 h of 
treatment (Fig. 4.10D), and KN-62 only had a modest effect.  Collectively, these data 
show that chronic 10,12 CLA treatment robustly increases inflammatory PGF2α 
production in human adipocytes in vitro as it does in humans in vivo, and that this effect 
appears to be relatively independent of [Ca2+]i levels or CaMK activity.  
 
10, 12 CLA-mediated insulin resistance is prevented by KN-62.  
KN-62 blocked 10,12 CLA suppression of PPARγ protein levels after 48 h of 
treatment (Fig. 4.11A), while TMB-8 had no effect.  Similarly, KN-62 blocked 10,12 
CLA induction of SOCS-3 gene expression (Fig. 4.11B) and attenuation of insulin-
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stimulated glucose uptake after 48 h of treatment (Fig. 4.11C), but TMB-8 had no effect 
(data not shown).  These data demonstrate that chronic treatment with 10,12 CLA causes 
insulin resistance in human adipocytes, which is dependent on CaMK activation, but not 
directly on calcium release from the ER.   
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Figure 4.1.  10,12 CLA increases [Ca2+]i. Cultures of newly differentiated human 
adipocytes were preloaded with 5 uM Fluo-3 AM.  Cultures were subsequently injected 
with BSA vehicle, 1ug/ml ionomycin (positive control), 30 uM 10,12 CLA, 30 uM 9,11 
CLA, or vehicle (BSA). Emitted fluorescence intensities were collected over time using a 
multi-detection microplate reader.  Excitation wavelength was 485 nm and fluorescence 
was collected at 528 nm.  Means (± SE; n=3) are representative of three independent 
experiments.   
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Figure 4.2.  10,12 CLA increase of [Ca2+]i is attenuated by BAPTA or TMB-8, but 
not EGTA.    Cultures of newly-differentiated human adipocytes were preloaded with 5 
uM Fluo-3 AM.  A: Cultures were injected with 1 ug/ml ionomycin (positive control) in 
the absence or presence of 20 uM BAPTA pretreatment. B: Cultures were injected with 
30 uM 10,12 CLA in the absence or presence of 2, 10, or 20 uM BAPTA pretreatment.  
C: Cultures were injected with thapsigargin (positive control) in the absence or presence 
of 100 uM TMB pretreatment.  D: Cultures were injected with 30 uM 10,12 CLA in the 
absence or presence of 1, 10, or 100 uM TMB pretreatment.  E: Cultures were injected 
with 1ug/ml ionomycin in the absence or presence of 500 uM EGTA pretreatment.  F: 
Cultures were injected with 30 uM 10,12 CLA in the absence or presence of 5, 50, or 500 
uM EGTA pretreatment.  Emitted fluorescence intensities were collected over time using 
a multi-detection microplate reader.  Excitation wavelength was 485 nm and fluorescence 
was collected at 528 nm.  Means (± SE; n=3) are representative of three independent 
experiments. 
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Figure 4.3.  10,12 CLA increase of ROS is attenuated by BAPTA, TMB-8, and KN-
62.    Cultures of newly-differentiated human adipocytes were serum-starved ~24 h and 
then preloaded with DCF for 1 h. Cultures were pretreated for 1 h with 2 uM BAPTA (B), 
10 uM KN-62 (K), or 100uM TMB-8 (T) and then treated with BSA or 10, 12 CLA for 3 
h.  Emitted fluorescence intensities were measured using a multi-detection microplate 
reader. Excitation wavelength was 485 nm and fluorescence was collected at 528 nm.  
Means (+SE; n=12) are representative of three independent experiments.   
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Figure 4.4.  10,12 CLA activation of ERK1/2 and JNK are attenuated by BAPTA, 
TMB-8, and KN-62.  A: Cultures of newly differentiated human adipocytes were treated 
for 12 h with BSA vehicle (V), 50 uM 10,12 CLA alone (10), 50 uM 9,11 CLA alone (9), 
or 50 uM  10,12 CLA in the presence of  2 uM BAPTA (10+B), 10 uM KN-62 (10+K), 
or 100 uM TMB-8 (10+T).  Proteins were then harvested, subjected to electrophoresis, 
and immunoblotted using a p-ERK and total ERK.  B: Cultures were treated with BSA 
vehicle or 50 uM 10,12 CLA for 6, 12, 24, or 48 h and then immunoblotted for p-JNK, 
total JNK and ATF3.  C: Cultures were treated for 12 h with BSA vehicle (V) 50 uM 
9,11CLA, or 50 uM 10,12 CLA (10) and immunoblotted as in B.  D: Cultures were 
treated for 12 h with BSA vehicle (V) or 50 uM 10,12 CLA (10) alone or 10,12 CLA in 
the presence of 2 uM BAPTA (10+B), 10 uM KN-62 (10+K), or 100 uM TMB-8 (10+T) 
and immunoblotted as in B. Data in all panels are representative of three independent 
experiments. 
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Figure 4.5. 10,12 CLA-mediated activation of NFκB-DNA binding is attenuated by 
TMB-8. A,B: Cultures of newly differentiated SGBS cells were treated for 640 min with 
BSA vehicle (V), 30 uM 10,12 CLA (10) in the absence or presence of 100uM TMB-8 
(T). ChIP assays quantified DNA binding of NFκB to the IL-8 (A) and COX-2 (B) 
proximal promoters using real-time PCR with primers positioned at NFκB response 
elements (black bars). Primers positioned at the β-globin promoter (white bars) were used 
as “no binding” control. Results are shown as percent recovery relative to input. Results 
are representative of at least three independent experiments. 
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Figure 4.6.  Time course of CLA-mediated increase in stress-related gene expression. 
Cultures of newly-differentiated human adipocytes were serum-starved for ~24 h and 
then treated for 6, 12, 24, or 48 h with BSA vehicle (○), 30 uM cis-9, trans-11 CLA (□), 
or 30 uM trans-10, cis-12 CLA (▲), and then harvested.  RNA was isolated and the 
mRNA levels of ATF3, CHOP, GADD34, and GAPDH (load control) were measured 
using real time qPCR.  Means (+SE; n=2) with asterisks (*) differ significantly (p<0.05) 
from the BSA controls at each time point, and are representative of at least two 
independent experiments. 
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Figure 4.7. Time course of CLA-induced inflammatory gene expression.  Cultures of 
newly-differentiated human adipocytes were serum-starved for ~24 h and then treated for 
6, 12, 24, or 48 h with BSA vehicle (○), 30 uM cis-9, trans-11 CLA (□), or 30 uM trans-
10, cis-12 CLA (▲), and then harvested.  RNA was isolated and the mRNA levels of 
interleukin (IL)-6, IL-8, COX-2, and GAPDH were measured using real time qPCR.  
Means (+SE; n=2) with asterisks (*) differ significantly (p<0.05) from the BSA controls 
at each time point, and are representative of at least two independent experiments. 
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Figure 4.8.  10,12 CLA-induced expression of inflammatory and stress-related genes 
are attenuated by BAPTA, TMB-8, and KN-62.  Cultures of newly differentiated 
human adipocytes were treated for 12 h with BSA vehicle (V), 50 uM 10,12 CLA alone 
(10), or 10,12 CLA in the presence of 2 uM BAPTA (10+B), 10 uM KN-62 (10+K), or 
100 uM TMB-8 (10+T).  Subsequently, RNA was subsequently isolated and the mRNA 
levels of IL-8, IL-6, COX-2, ATF-3, CHOP, GADD34, and GAPDH were measured by 
real time qPCR.  Data are normalized to the vehicle controls. Means (+ SE; n=2) that do 
not share a common lower case letter differ (P<0.05).  Data are representative of three 
independent experiments. 
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Figure 4.9.  10,12 CLA increase of  [Ca2+]i and ROS levels and expression of 
inflammatory and stress-related genes are dependent on PLC.  A: Cultures of newly 
differentiated human adipocytes were preloaded with 5 uM Fluo-3 AM.  Cultures were 
injected with 50 uM 10,12 CLA in the absence or presence of 25, 50, or 100 uM D609 
pretreatment. Emitted fluorescence intensities were collected over time using a multi-
detection microplate reader. Excitation wavelength was 485 nm and fluorescence was 
collected at 528 nm. Means (+SE; n=3) are representative of two independent 
experiments.  B: Cultures of newly differentiated human adipocytes were preloaded with 
DCF for 30 min.  Cultures were then pretreated with 50uM D609 (D) followed by 3 h 
treatment with BSA (V) or 50 uM 10,12 CLA (10). Emitted fluorescence intensities were 
measured using a multi-detection microplate reader. Excitation wavelength was 485 nm 
and fluorescence was collected at 528 nm. Means (+ SE; n = 3-12) are representative of 
three independent experiments. C:  Cultures were pretreated for 30 min with 50 uM D609 
(D) followed by 12 h treatment with BSA vehicle (V) or 50 uM 10,12 CLA (10).  RNA 
was subsequently isolated and mRNA levels of IL-8, COX-2, ATF-3, GADD34, and 
GAPDH were measured by real time qPCR.  Data are normalized to the vehicle controls. 
Means (+ SE; n=2) that do not share a common lower case letter differ (P<0.05).  Data 
are representative of three independent experiments. 
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Figure 4.10.  10,12 CLA activation of the inflammatory PG pathway is not 
dependent on [Ca2+]i.  A: Cultures of newly-differentiated human adipocytes were 
treated with BSA vehicle (V) or 30 uM 10,12 CLA (10) for 6, 12, or 24 h. Cells were 
harvested and immunoblotted for p-PLA2 and total PLA2.  Data are representative of 
three experiments.   B: Cultures were treated for 12 h with BSA vehicle (V), 30 uM 9,11 
CLA (9) or 30 uM 10,12 CLA (10), and immunoblotted as in A. Data are representative 
of three experiments.   C: Cultures were treated for 12 h with BSA vehicle (V), 50 uM 
10,12 CLA alone (10), or 10,12 CLA in presence of 2 uM BAPTA (10+B), 10 uM KN-
62 (10+K), or 100 uM TMB-8 (10+T), and immunoblotted as in A. Data are 
representative of three experiments.  D: Cultures were treated for 24 h with BSA vehicle 
(V), 50 uM 10,12 CLA alone (10), or 10,12 CLA in the presence of 2 uM BAPTA 
(10+B), 10 uM KN-62 (10+K), or 100 uM TMB-8 (10+T).  Conditioned media were 
subsequently collected and PGF2α levels were measured using a commercially available 
EIA kit.  Means (+ SE; n=3) not sharing a common lower case letter differ (P<0.05). 
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Figure 4.11.  10,12 CLA-mediated insulin resistance is attenuated by KN-62.  A: 
Cultures of newly-differentiated human adipocytes were treated for 48 h with BSA 
vehicle (V), 50 uM 10,12 CLA (10), 10,12 CLA + 10 uM KN-62 (10+K), 10,12 CLA + 
100uM TMB (10+T), 10uM KN-62 (K) or 100uM TMB-8 (T). Cultures were harvested 
and immunoblotted for PPARγ and GAPDH.   B: Cultures were treated for 48 h with 
BSA vehicle (V), 50 uM 10,12 CLA alone (10), or 10,12 CLA in the presence of 10 uM 
KN-62 (10+K).  Cells were harvested for RNA and SOCS-3 and GAPDH were measured 
by qPCR.  C: Cultures were treated for 48 h with BSA vehicle (V), 50 uM 10,12 CLA 
alone (10), or 10,12 CLA in the presence of 10 uM KN-62 (10+K).  Uptake of basal or 
insulin-stimulated [3H]-2-deoxy-glucose was subsequently measured in cultures treated 
without (-) or with (+) insulin.  Means (+ SE; n=3) that do not share a common lower 
case letter differ (P<0.05).  Data are representative of three independent experiments. 
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Figure 4.12. Working model: 10,12 CLA-mediated oxidative stress, inflammation, 
and insulin resistance are regulated, in part, by [Ca2+]i.   Acutely, 10,12 CLA induces 
an rapid and robust elevation of [Ca2+]i. levels, which are dependent on PLC activity and 
mobilization of calcium from the ER. This increase activates ROS and CAMK II, which 
in turn activate MAPK and NFκB that trigger ISR and inflammatory gene expression.  
Independent of calcium, 10,12 CLA activates the inflammatory PG pathway involving 
PLA2 and PGF2α within 12-24 h of treatment, respectively.  Chronically, these CLA-
induced signals antagonize PPARγ, causing insulin resistance after 48 h of treatment. 
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Discussion 
 [Ca2+]i. regulates a myriad of vital cell processes by activating diverse signaling 
cascades,  many of which require calcium-binding proteins like CaM.  Calcium-activated 
CaM regulates the activity of a variety of enzymes including CaMKs and phosphorylases 
involved in inflammatory and stress responses (Colomer et al. 2007).  For these reasons, 
influx of calcium from extracellular sources (e.g., plasma membrane ion channels) and 
efflux from intracellular stores (e.g., ER, mitochondria) are tightly regulated.   
 The purpose of this study was to determine the role of [Ca2+]i. in mediating 10,12 
CLA-induced ROS production, inflammatory gene and protein expression, and insulin 
resistance in human adipocytes.  To our knowledge, data presented in this article are the 
first to demonstrate that 10,12 CLA rapidly (1 min) increases [Ca2+]i. levels in human 
adipocytes in an isomer- and site-specific manner (Figs. 4.1-4.2). Futhermore, blocking 
[Ca2+]i. accumulation and inhibiting PLC or CaMK activity prevented 10,12 CLA-
mediated 1) production of ROS within 3 h (Fig. 4.3), 2) activation of ERK1/2, JNK, or 
NFκB within 6-10 h (Figs. 4.4-4.5), and 3) induction of ISR/ER stress or inflammatory 
genes within 6-12 h (Fig. 4.6-4.9).  Chronically (48 h), inhibiting CaMK activity 
suppressed 10,12 CLA-mediated insulin resistance (Fig. 4.11).  Taken together, these 
data provide support for our working model shown in Fig. 4.12, hypothesizing that 10,12 
CLA’s impact on calcium signaling and markers of inflammation and insulin resistance 
occurs in two response phases.  The initial response to CLA begins with a rapid and 
robust release of calcium from the ER that leads to ROS production, MAPK and NFκB 
activation, and ISR and inflammatory gene expression. The second and more chronic 
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response begins with PLA2 activation and PGF2α production that is independent of 
calcium.  This causes another phase of calcium signaling that further activates CaMK II, 
leading to the suppression of PPARγ and the development of insulin resistance.   
 In support of our findings, calcium and ROS have been implicated in the 
activation of NFκB and inflammation (Pahl et al. 1996).  Likewise, we found that 
blocking calcium signaling with BAPTA, TMB, or KN62 prevented CLA-mediated ROS 
production (Fig. 4.3), suggesting an increase in [Ca2+]i. levels precedes ROS production 
in human adipocytes.  Furthermore, these compounds attenuated 10,12 CLA-mediated 
activation of MAPKs (Fig. 4.4) and NFκB (Fig. 4.5), and the expression of ISR/ER stress 
and inflammatory genes (Fig. 4.8).  The PLC inhibitor D609 attenuated 10,12 CLA 
increase in [Ca2+]i. levels, ROS, and inflammatory gene expression (Fig. 4.9).  
Collectively, these data demonstrate the important role of [Ca2+]i. in mediating the 
inflammatory and stress responses to 10,12 CLA in cultures of human adipocytes. 
 The prevention of CLA-mediated insulin resistance by KN-62, but not TMB-8, 
suggests that 10,12 CLA increased [Ca2+]i. levels from sources other than just the ER.  
Although KN-62 was initially identified as a calcium-CaMK II inhibitor, this inhibitor 
has also been reported to block voltage-sensitive channels (Tokumitsu et al. 1990, 
Tornquist et al. 1996, Cui et al. 1996, Marley et al. 1996). Thus, it seemed possible that 
10,12 CLA increases Ca2+ influx across the plasma membrane.  However, KN-62 (data 
not shown) and the extracellular calcium chelator EGTA did not dramatically affect 
10,12 CLA’s increase of [Ca2+]i. (Fig. 4.2), suggesting that extracellular calcium influx is 
not a major source of CLA-induced [Ca2+]i..  In agreement with other studies, the 
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phosphatidylcholine-specific (PC)-PLC inhibitor D609 (Fig. 4.9a), attenuated 10,12 
CLA-mediated increase in [Ca2+]i. levels.  Activation of PC-PLC has been reported to 
increase [Ca2+]i. levels via conversion of diacylglycerol (DAG) by DAG kinase to 
phosphatidic acid, which mobilizes calcium from inositol 1,4,5-triphosphate-independent 
calcium pools (Camina et al. 1999, Andrei et al. 2004, Suh et al. 2008).  Therefore, it 
appears that 10,12 CLA stimulates an efflux of calcium from intracellular stores like the 
ER, rather than an influx of calcium from extacellular sources. 
 The mitochondria can also store and release calcium, potentially providing 
another source of [Ca2+]i. for signaling (Butow et al. 2004). Mitochondrial dysfunction or 
stress, similar to ER stress, can adversely affect the mitochondria’s capacity for calcium 
storage or regulated release, thereby increasing [Ca2+]i. levels.  For example, treating cells 
with a mitochondria uncoupler increases [Ca2+]i. levels, thereby activating ERK1/2 (Luo 
et al. 1997).  Similarly, impairing mitochondrial respiration increases [Ca2+]i. levels and 
activates CaMK IV (Arnould et al. 2002).  We investigated whether 10,12 CLA could 
affect mitochondria function by examining two indicators of altered mitochondrial 
membrane potential or integrity (e.g., the JC-1 assay and cytochrome C release from 
mitochondria, respectively). Neither marker of mitochondrial dysfunction was affected 
by 10,12 CLA (data not shown), suggesting that acute 10,12 CLA treatment does not 
directly cause mitochondrial dysfunction. 
 CaMK II has been reported to phosphorylate ERK1/2 in response to G protein-
coupled receptor (GPCR) agonists, depolarizing stimuli, or ionophores that lead to 
increased free [Ca2+]i. levels (Borodinsky et al. 2002, Ginnan et al. 2004, Huang et al. 
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2004, Lu et al. 2005).  Similarly, we previously demonstrated that the GPCR antagonist 
pertussis toxin blocked 10,12 CLA-mediated activation of ERK1/2 (Brown et al. 2004). 
In this study, we demonstrated the KN-62 also attenuates 10,12 CLA phosphorylation of 
ERK1/2 and JNK (Fig. 4.4).  KN-93, another CaMK inhibitor, has also been shown to 
attenuate LPS activation of ERK1/2, JNK, NFκB, and AP-1 activation (Cuschieri et al. 
2005).  Collectively, these data support our hypothesis that CLA’s activation of ERK1/2 
and JNK are closely linked to [Ca2+]i. and CaMK activity. 
 We provide data demonstrating that the CaMK II inhibitor KN-62 prevents 10,12 
CLA-mediated insulin resistance (Fig. 4.11).  Elevated [Ca2+]i. levels have been linked to 
insulin resistance in insulin-sensitive cells (Draznin et al. 1987, Draznin et al. 1988, 
Begum et al. 1993), including rat adipocytes (Draznin et al. 1989). In vivo, BAPTA was 
shown to reverse insulin resistance in rats fed a high fat diet (Jang et al. 2002).  
Unfortunately, we could not use BAPTA for our glucose uptake studies due to its toxicity 
when used chronically (48 h).  Future studies using gene silencing techniques may be 
able to define the specific role of CaMK signaling and insulin sensitivity in CLA-treated 
cultures of human adipocytes. 
 10,12 CLA delipidation of murine adipocytes in vivo and in vitro has recently 
been linked to the ISR pathway (LaRosa et al. 2007).  These authors demonstrated that 
10,12 CLA, but not 9,11 CLA, induced markers of the ISR pathway in mouse and 3T3-
L1 adipocytes.  They also suggest that the ISR precedes the later induction of 
inflammatory gene expression, and contributes to delipidation by 10,12 CLA.  Our data 
in cultures of human adipoctyes are similar to these published data in murine adipocytes.  
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10,12 CLA has also been shown to cause atypical ER stress in a murine mammary 
carcinogenesis model (Ou et al. 2008).  Similarly, the rapid (1 min) increase in [Ca2+]i.  
levels by 10,12 CLA appears to increase ROS production (3 h) and activate specific 
MAPKs (6 h) and ISR/ER stress response genes (6-12 h) relatively early, which, in turn, 
lead to chronic (48 h) activation of CaMK and subsequent insulin resistance in cultures of 
human adipocytes.  However, the specific mechanism by which 10,12 CLA increases 
[Ca2+]i. and ISR/ER stress, and the extent to which these early upstream signals are 
responsible for adipocyte delipidation, are still unknown. 
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CHAPTER V 
 
 
CONJUGATED LINOLEIC ACID-MEDIATED INFLAMMATION AND 
INSULIN RESISTANCE IN HUMAN ADIPOCYTES ARE ATTENUATED BY 
RESVERATROL
 
 
 
The following chapter was previously published in the Journal of Lipid Research 
volume 50, pages 225 to 232, in 2009.  The coauthors of the article were Angel Overman, 
Kathleen LaPoint, Robin Hopkins, Tiffany West, Chia-Chi Chuang, Kristina Martinez, 
Doris Bell, and Michael McIntosh.  Permission from the publisher to use the article in its 
entirety can be found in Appendix A.  References from this article can be found in the 
Reference section. 
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Abstract 
Inflammation plays a role in trans-10, cis-12 (10,12) conjugated linoleic acid 
(CLA)-mediated delipidation and insulin resistance in adipocytes.  Given the anti-
inflammatory role of resveratrol (RSV), we hypothesized that RSV would attenuate 
inflammation and insulin resistance caused by 10,12 CLA in human adipocytes.  RSV 
blocked 10,12 CLA induction of the inflammatory response by preventing activation of 
extracellular signal related kinase (ERK) and induction of inflammatory gene expression 
(i.e., IL-6, IL-8, IL-1β) within 12 h.  Similarly, RSV suppressed 10,12 CLA-mediated 
activation of the inflammatory prostaglandin (PG) pathway involving phospholipase A2, 
cyclooxygenase-2 (COX-2), and PGF2α.  In addition, RSV attenuated 10,12 CLA increase 
of intracellular calcium and reactive oxygen species (ROS) associated with cellular stress, 
and activation of stress-related proteins (i.e., ATF3, JNK) within 12 h. 10,12 CLA-
mediated insulin resistance and suppression of fatty acid uptake and triglyceride content 
were attenuated by RSV. Lastly, 10,12 CLA-mediated decrease of peroxisome 
proliferator activated receptor (PPAR)γ protein levels and activation of a peroxisome 
proliferator response element (PPRE) reporter were prevented by RSV. RSV increased 
the basal activity of the PPRE, suggesting RSV increases PPARγ activity. Collectively, 
these data demonstrate for the first time that RSV prevents 10,12 CLA-mediated insulin 
resistance and delipidation in human adipocytes by attenuating inflammation and cellular 
stress and increasing PPARγ activity.   
 
 
94 
Introduction 
Feeding a mixture of conjugated linoleic acid (CLA) isomers (i.e., trans-10, cis-12 
[10,12] CLA and cis-9, trans-11 [9,11] CLA) reduces adiposity in animals (House et al. 
2005) and some humans (Whigman et al. 2007). The triglyceride (TG) lowering 
properties of CLA appear to be due exclusively to the 10,12 isomer (Park et al. 1999, 
Brown et al. 2001, Brown et al. 2003), and involve decreased uptake and metabolism of 
glucose (Brown et al. 2004), and increased lipolysis (Chung et al. 2005) in adipocytes. 
These antiobesity properties of 10,12 CLA are dependent on the activation of 
mitogen-activated protein kinase kinase/extracellular signal-related kinase (MEK/ERK) 
(Brown et al. 2004) and nuclear factor κB (NFκB) (Chung et al. 2005, Poirier et al. 2006) 
in adipocytes. These signaling pathways induced by 10,12 CLA are linked to the 
induction and secretion of cytokines (Chung et al. 2005, Poirier et al. 2006), which are 
known to antagonize peroxisome proliferator activated receptor (PPAR)γ target gene 
expression and insulin sensitivity (Suzawa et al. 2003, Adams et al. 1997, Chung et al. 
2006, Kennedy et al. 2008, Lui et al. 2007, Purushotham et al. 2007).  Consistent with 
these data, 10,12 CLA supplementation of humans is associated with hyperglycemia, 
insulin resistance, elevated levels of inflammatory prostaglandins (PG)s and cytokines, 
and dyslipidemia (Riserus et al. 2002, Riserus et al. 2002, Tholstrup et al. 2007).   
Recently, supplementation of mice and 3T3-L1 adipocytes with 10,12 CLA has 
been shown to activate the integrated stress response (ISR) pathway (LaRosa et al. 2007), 
which is linked to inflammation, insulin resistance, and endoplasmic reticulum (ER) 
stress (Gregor et al. 2007).  Cellular stress can be caused by a relatively disproportional 
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influx of macronutrients that adversely affect organelle function, including the 
mitochondria and ER.  This cellular stress increases the release of calcium and reactive 
oxygen species (ROS), which leads to inflammation and/or insulin resistance (Gregor et 
al. 2007).  These stressors can impair the adipocyte’s ability to synthesize and/or store 
fatty acid (FA)s as TG, causing lipids to accumulate in non-adipocytes (e.g., hepatocytes, 
myotubes) and resulting in disorders like steatosis and insulin resistance, respectively 
(Lui et al. 2007).   Therefore, it is possible that 10,12 CLA, a trans conjugated FA not 
normally abundant in the diet, causes cellular stress in adipocytes, initiating a signaling 
cascade that adversely affects adipocyte function. These issues raise concern about the 
safe and effective use of supplements containing 10,12 CLA as dietary strategy for 
weight loss. 
Resveratrol (RSV), a phenolic phytochemical found in grapes, berries, and 
peanuts, has been shown to inhibit tumor necrosis factor (TNF)α-induced inflammatory 
gene expression and secretion in 3T3-L1 adipocytes (Ahn et al. 2007).  In mice, 
supplementing a high saturated FA diet with RSV increased lifespan, motor activity, 
AMP kinase, and insulin sensitivity (Baur et al. 2006) and reduced adipocyte size and 
metabolic disease (Lagouge et al. 2006) compared to a high saturated FA diet alone.  
These and other studies (Saiko et al. 2008) suggest that low micromolar blood levels of 
RSV protect against inflammatory- and stress-related diseases. However, the 
mechanism(s) by which RSV protects against the development of these diseases are not 
fully understood, and its impact on CLA-mediated inflammation is unknown. 
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Therefore, we wanted to determine the extent to which RSV prevented some of 
the side effects (i.e., inflammation, cellular stress, insulin resistance) associated with 
CLA supplementation.  To begin to answer this question, we examined the isomer-
specific influence of CLA in the absence and presence of RSV on 1) the induction or 
activation of genes, proteins, PGs, ROS, and intracellular calcium levels [Ca+2]i 
associated with inflammation and cellular stress, 2) insulin-resistance, 3) FA uptake and 
TG content, and 4) the protein levels and activity of PPARγ. 
 
Materials and Methods 
Materials 
All cell culture ware were purchased from Fisher Scientific (Norcross, GA). 
Western lightning chemiluminescence substrate was purchased from Perkin Elmer Life 
Science (Boston, MA).  Immunoblotting buffers and precast gels were purchased from 
Invitrogen (Carlsbad, CA). DNA-free was purchased from Ambion (Austin, TX).  Gene-
specific primers were purchased from Applied Biosystems (Forest City, CA).  Polyclonal 
antibodies for anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (sc20357), 
activating transcription factor (ATF) 3, and β-actin (sc1616) were obtained from Santa 
Cruz Biotechnology (Santa Cruz, CA).  Anti-P (Ser505) phospholipase A2 (PLA2), anti-P 
(Thr183/185) c-JunNH2-terminal kinase (JNK), and anti-P (Thr-202/204) and total 
ERK1/2 antibodies were purchased from Cell Signaling Technologies (Beverly, MA).  
PGF2α levels were measured in conditioned media using an Enzyme Immunoassay (EIA) 
kit from Caymen Chemicals (Ann Arbor, MI).  Fetal bovine serum (FBS) was purchased 
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from Hyclone (Logan, UT).  The thiazolidinedione (TZD) BRL (Rosiglitazone) was a 
generous gift from Dr. Per Sauerberg, Novo Nordisk, Denmark.  Isomers of CLA (+98% 
pure) were purchased from Matreya (Pleasant Gap, PA) or Natural ASA (Hovdebygda, 
Norway). The Nucleofactor and Dual Glo luciferase kits were obtained from Amaxa 
(Cologne, Germany) and Promega (Madison, WI), respectively. Dichlorofluorescein 
(DCF) and Fluo-3 acetoxymethyl ester (Fluo-3 AM) were purchased from Molecular 
Probes (Eugene, OR). All other reagents and chemicals were purchased from Sigma 
Chemical (St. Louis, MO) unless otherwise stated. 
 
Culturing of human primary adipocytes 
Abdominal white adipose tissue (WAT) was obtained from non-diabetic females, 
between the ages of 20-50 years old with a body mass index (BMI) ≤ 30 during 
abdominoplasty.  Consent was obtained from the Institutional Review Board at the 
University of North Carolina at Greensboro.  Tissue was digested using collagenase and 
stromal vascular (SV) cells were isolated as previously described (Brown et al. 2004). 
Cultures containing ~50% preadipocytes and ~50% adipocytes were treated between day 
6-12 of differentiation. Each experiment was repeated at least twice at different times 
using a mixture of cells from 2-3 subjects unless otherwise indicated.   
 
Preparation of FAs 
Both isomers of CLA were complexed to FA-free (>98%) bovine serum albumin 
(BSA; Sigma #A-7030) at a 4:1 molar ratio using 1 mmol/L BSA stocks.  This specific 
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type of BSA has a relatively low inflammatory capacity compared to at least 10 different 
types of BSA we have tested in our lab. 
 
Immunoblotting 
Immunoblotting was conducted as we previously described (Brown et al. 2004).  
 
Measuring [Ca2+]i levels 
[Ca2+]i levels were measured using Fluo-3 AM.  Briefly, cells were preloaded 
with 5 uM Fluo-3 AM and 10% Pluronic F-127, an anionic detergent at 25˚C for 30 min 
in the dark.  Cells were then washed with a buffer consisting of HBSS, CaCl2, and 
probenecid, which prevents Fluo-3 leakage from cells, and baseline fluorescence was 
measured using a Synergy Multi-detection Microplate Reader (Bio-Tek Inc, Winooski, 
VT).  Cells were then treated in the absence or presence of CLA or BSA vehicle in the 
absence and presence of RSV.  Fluorescence was monitored for 10 sec intervals for 5 min. 
Excitation wavelength was 485 nm and fluorescence was collected at 528 nm. Changes in 
the ratio of calcium-dependent fluorescence over prestimulus background fluorescence 
(F/F0) are plotted over time in single representative experiments. 
 
Measuring ROS levels 
For the DCF assay, primary human adipocytes were seeded in 96-well plates and 
differentiated for 6 days.  On day 6, media was changed to serum- and phenol red-free 
media for 24 h.  Following 24 h, cells were treated with various treatments for 3 h.  Cells 
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were then spiked and incubated with 5uM DCF and placed at 37° C for 1 h.  Cells were 
then washed once with HBSS and fluorescence was immediately measured in a plate 
reader with an excitation/emission wavelength of 485/528nm.  DCF values were 
calculated after normalizing background fluorescence levels of DCF. 
 
Transient transfections of human adipocytes 
For measuring PPARγ activity, primary human adipocytes were transiently 
transfected with the multimerized PPRE-responsive luciferase (luc) reporter construct 
pTK-PPRE3x-luc (Kliewer et al. 1992) using the Amaxa Nucleofactor as previously 
described (Chung et al. 2005). On day 6 of differentiation, 1 x 106 cells from a 60 mm 
plate were trypsinized and resuspended in 100 µL of nucleofector solution (Amaxa) and 
mixed with 2 µg of pTK-PPRE3x-luc and 25 ng pRL-CMV for each sample. 
Electroporation was performed using the V-33 nucleofector program (Amaxa). Cells 
were replated in 96-well plates after 10 min recovery in calcium-free RPMI media. 
Firefly luciferase activity was measured using the Dual-Glo luciferase kit and normalized 
to Renilla luciferase activity from the co-transfected control pRL-CMV vector. All 
luciferase data are presented as a ratio of firefly luciferase to Renilla luciferase activity.   
 
RNA isolation and real time PCR 
Total RNA was isolated from the cultures using Tri Reagent purchased from 
Molecular Research Center (Cincinnati, OH) according to manufacturer’s protocol.  For 
real time qPCR, 2.0 ug total RNA was converted into first strand cDNA using Applied 
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Biosystems High-Capacity cDNA Archive Kit. qPCR was performed in an Applied 
Biosystems 7500 FAST Real Time PCR System using Taqman Gene Expression Assays.  
To account for possible variation related to cDNA input or the presence of PCR inhibitors, 
the endogenous reference gene GAPDH was simultaneously quantified for each sample, 
and data were normalized accordingly.  
 
Lipid staining 
Lipid staining was conducted using Oil-Red-O (ORO) as previously described 
(Brown et al. 2003).  The TG levels were measured using a modified, commercially-
available TG assay as previously described (Brown et al. 2003). The protein content was 
determined using the BioRad’s BCA assay. 
 
 2-[3H]deoxy-glucose and [14C]oleic acid uptake 
Following the experimental treatments for 48 h, insulin-stimulated uptake of 2-
[3H]deoxy-glucose and [14C]oleic acid were measured following a 90 min incubation in 
the presence of 100 nmol/L human insulin as described previously (Brown et al. 2004).   
 
Statistical analysis  
Statistical analyses were performed for data in Figures 5.1D, 5.2B, 5.3D, 5.4A,B, 
and 5.5B,C by testing the main effects of CLA (BSA, CLA) and RSV (- or + RSV) and 
their interaction (CLA x RSV) using two-way ANOVA (JMP Version 6.03, SAS 
Institute; Cary, NC).  For data in Figure 5.2C, a two way ANOVA of the main effects 
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Treatment (BSA, 9,11 CLA, 10,12 CLA, 10,12 CLA+RSV) and Time (6, 12, 24, 48 h) 
and their interactions for each dosage was conducted.  A one-way ANOVA was 
conducted for data in Figures 5.1C, 5.3B, and 5.6B,C.  Student’s t tests were used to 
compute individual pairwise comparisons of least square means (P<0.05).  Data are 
expressed as means ± S.E.   
  
Results 
RSV blocks 10,12 CLA induction of inflammation and stress-related signaling. 
A preliminary dose response study showed that 50 uM RSV most-effectively 
decreased the activation of ERK1/2 (Fig. 5.1A) and JNK (data not shown), and 
expression of inflammation genes (Fig. 5.1C) caused by 10,12 CLA without reducing cell 
viability.  Thus, we examined the extent to which 50 uM RSV prevented inflammation 
caused by 50 uM 10,12 CLA in human adipocytes. RSV attenuated 10,12 CLA activation 
of ERK1/2 (Fig. 5.1B) and induction of IL-6, IL-8, and IL-1β gene expression (Fig. 
5.1D)  within 12 h. Similarly, RSV blocked 10,12 CLA induction of the inflammatory PG 
pathway (Fig. 5.2A = PLA2,  5.2B = COX-2,  5.2C = PGF2α).  Next, we examined the 
influence of RSV on [Ca+2]i and ROS levels in CLA-treated cultures. RSV attenuated the 
rapid, 10,12 CLA increase in [Ca+2]i and ROS (Fig. 5.3A = [Ca+2]i, 5.3B = ROS), events 
directly linked to cellular stress, inflammation, and insulin resistance (Gregor et al. 2007, 
Houstis et al. 2006).  Similarly, RSV attenuated 10,12 CLA activation of the stress-
related proteins ATF3 and JNK (Fig. 5.3C), and the mRNA levels of ATF3 (Fig. 5.3D).  
RSV alone increased the levels of ATF3 mRNA and protein.  Taken together, these data 
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demonstrate that RSV attenuates 10,12 CLA-mediated inflammation and cellular stress in 
cultures of human adipocytes.  
 
10,12 CLA suppression of insulin sensitivity, FA uptake, and TG content are 
prevented by RSV. 
We previously demonstrated that 10,12 CLA causes insulin resistance, dependent 
on the activation of ERK1/2 (Brown et al. 2004) and NFκB (Chung et al. 2005).  Given 
the insulin sensitizing effects reported for RSV in rodents (Baur et al. 2006, Lagouge et al. 
2006, Sun et al. 2007), we speculated that RSV would improve insulin sensitivity in 
cultures of human adipocytes treated with 10,12 CLA.  Indeed, 10,12 CLA treated-
cultures co-supplemented with 50 uM RSV had higher levels of insulin-stimulated 
glucose uptake compared to cultures treated with 10,12 CLA alone (Fig. 5.4A).  
Consistent with these data, RSV blocked 10,12 CLA induction of the suppressor of 
cytokine synthesis (SOCS)-3, a protein that causes insulin resistance through serine 
phosphorylation of IRS-1.  RSV also attenuated 10,12 CLA suppression of adiponectin 
and sirtuin (SIRT)1 mRNA levels compared to cultures treated with 10,12 CLA alone, 
suggesting RSV enhances glucose and/or FA metabolism in these cultures (Fig. 5.4B).  
Similarly, RSV co-supplementation attenuated delipidation and suppression of FA uptake 
by 10,12 CLA (Fig. 5.5A-C).  Thus, RSV may enhance insulin-stimulated glucose and 
FA uptake in CLA-treated cultures by upregulating genes that stimulate metabolism. 
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10,12 CLA suppression of PPARγ inhibited by RSV. 
To determine the mechanism by which RSV improves insulin sensitivity and 
reduces delipidation, we examined the extent to which RSV enhanced the protein levels 
and activity of PPARγ, a transcription factor that enhances glucose and FA uptake and 
utilization.  RSV prevented CLA-mediated decrease of PPARγ protein levels (Fig. 5.6A).  
To determine whether RSV blocks CLA-suppression of PPARγ activity, the ligand-
induced activation of a PPRE-luciferase reporter construct was measured.  10,12 CLA-
mediated suppression of the BRL-activated PPRE reporter was prevented by co-
supplementation with RSV (Fig. 5.6B), suggesting that RSV prevents CLA suppression 
of ligand-stimulated PPARγ activity. Concordantly, RSV increased the activation of the 
PPRE reporter in a dose-dependent manner in the absence of BRL (Fig. 5.6C).  
Collectively, these data support our hypothesis that RSV enhances insulin sensitivity and 
TG content of 10,12 CLA-treated human adipocytes by increasing the activity and/or 
protein expression of PPARγ. 
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Figure 5.1.  RSV attenuates 10,12 CLA activation of ERK1/2 and induction of 
cytokines. Cultures of newly-differentiated human adipocytes were serum-starved for 
~24 h and then treated for 12 h with BSA vehicle or 50 uM 10,12 CLA in the absence (-) 
or presence (+) of 0, 10, 25, or 50 uM RSV (R).  Subsequently, cultures were harvested 
for the determination of the protein levels of P-ERK1/2 and total (T)-ERK1/2 by 
immunoblot (A, B) or mRNA levels for IL-6, IL-8, and IL-1β by real time qPCR (C, D).  
A, B:  Data are representative of one (A) or at least three (B) independent experiments. C: 
D: Data are representative of one (C) or at least three (D) independent experiments. 
Means (+ S.E.; n=2 for C, and n=3 for D) not sharing a lower case letter differ 
significantly (p<0.05). The RSV dose in B and D was 50 uM.  
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Figure 5.2.  RSV attenuates 10,12 CLA activation of the inflammatory PG pathway. 
(A= PLA2, B= COX-2, C= PGF2α). Cultures of newly-differentiated human adipocytes 
were serum-starved for ~24 h and then treated for either 12 h (A and B) or 6, 12, 24, or 
48 h (C) with BSA vehicle or 50 uM 10,12 CLA  in the absence (-) or presence (+) of 50 
uM RSV (R).  Subsequently, cultures were harvested for the determination of the protein 
levels of P-PLA2 and total (T)- PLA2 by immunoblot (A), mRNA levels for 
cyclooxygenase 2 (COX-2) by real time qPCR (B), or the secreted levels of PGF2α in 
conditioned media by enzyme immunoassay (C).  A: Data are representative of at least 
three independent experiments.  B: Means (+ S.E.; n=3) not sharing a lower case letter 
differ significantly (p<0.05), and are representative of at least three independent 
experiments.  C: Means (+ S.E.; n=4) with asterisks (*) differ significantly (p<0.05) from 
the BSA controls at each time point, and are representative of at least two independent 
experiments.  Means with number sign (#) are significantly lower than cultures treated 
with 10,12 CLA alone. 
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Figure 5.3.  RSV attenuates 10,12 CLA increase in intracellular calcium and 
indicators of cellular stress.  A: Cultures of newly differentiated human adipocytes were 
serum starved for ~24 h and then preloaded with 5 uM Fluo-3 AM.  Subsequently, 
cultures were injected with 30 uM 10, 12 CLA (▲), 30 uM 10,12 CLA + 50 uM RSV 
(CLA+R, ∆), BSA vehicle (BSA, ●), or BSA+RSV (BSA+R, ○ ).  Emitted fluorescence 
intensities were collected over time using a multi-detection microplate reader.  Excitation 
wavelength was 485 nm and fluorescence was collected at 528 nm.  Means (+S.E.; n=12) 
are representative of three independent experiments.   B: Cultures of newly differentiated 
human adipocytes were serum-starved ~24 h and then treated with 50 (□) or 150 uM (■) 
BSA, 9, 11 CLA, 10, 12 CLA, 10, 12 CLA + 50 uM RSV (R) or 50 uM RSV alone for 3 
h.  Cultures were then loaded with DCF for 1 h and emitted fluorescence intensities were 
measured using a multi-detection microplate reader. Excitation wavelength was 485 nm 
and fluorescence was collected at 528 nm.  Means (+ S.E.; n = 3-12) are representative of 
three independent experiments.  C, D: Cultures of newly-differentiated human adipocytes 
were serum-starved for ~24 h and then treated for 12 h with BSA vehicle or 50 uM 10,12 
CLA in the absence (-) or presence (+) of 50 uM RSV (R).  Subsequently, cultures were 
harvested for the determination of the protein levels of P-JNK, total (T)-JNK, ATF3, and 
β-actin by immunoblot (C) or mRNA levels for ATF3 by real time qPCR (D).  C: Data 
are representative of at least three independent experiments.  D: Means (+ S.E.; n=3) not 
sharing a lower case letter differ significantly (p<0.05), and are representative of at least 
two independent experiments. 
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Figure 5.4.  RSV blocks 10,12 CLA-mediated insulin resistance.  Cultures of newly-
differentiated human adipocytes were serum-starved for ~24 h and then treated for either 
48 h (A) or 24 h (B) with BSA vehicle or 50 uM 10,12 CLA in the absence (-) or 
presence (+) of 50 uM RSV (R).  A: Insulin-stimulated glucose uptake using 2-
[3H]deoxyglucose (2-DOG) was measured after a 90 min incubation in the presence of 
insulin.  Means (+ S.E.; n=6) not sharing a lower case letter differ significantly (p<0.05).  
B: The mRNA levels of suppressor of cytokine synthesis 3 (SOCS-3), adiponectin 
(APM-1), and SIRT-1 were measured by real-time PCR.  Means (+ S.E.; n=3) not 
sharing a lower case letter differ significantly (p<0.05), and are representative of at least 
two independent experiments. 
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Figure 5.5.  RSV attenuates delipidation by 10,12 CLA. Cultures of newly-
differentiated human adipocytes were treated in adipocyte media for 7 d with BSA 
vehicle or 50 uM 10,12 CLA in the absence (-) or presence (+) of 50 uM RSV (R).  Fresh 
media containing treatments were changed every 2 d.  Cultures were then either stained 
with Oil Red O and phase-contrast photomicrographs were taken using an Olympus 
inverted microscope with a 10X objective (A) or their TG content was measured using a 
commercially available TG assay kit (B). A: Data are representative of two independent 
experiments.  B: Means (+ S.E.; n=6) not sharing a lower case letter differ significantly 
(p<0.05).  C: Cultures of newly-differentiated human adipocytes were serum-starved for 
~24 h and then treated for either 48 h with BSA vehicle or 50 uM 10,12 CLA in the 
absence (-) or presence (+) of 50 uM RSV (R).  [14C]oleic acid uptake was measured after 
90 min incubation in the presence of insulin.  Means (+ S.E.; n=3) not sharing a lower 
case letter differ significantly (p<0.05).   
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Figure 5.6.  RSV inhibits 10,12 CLA suppression of PPARγ activity.  Cultures of 
newly-differentiated human adipocytes were serum-starved for ~24 h and then treated for 
24 h with BSA vehicle or 50 uM 10,12 CLA in the absence (-) or presence (+) of 50 uM 
RSV (R).  Subsequently, cultures were harvested for the determination of PPARγ and β-
actin protein levels by immunoblot (A).  B: Cultures of newly-differentiated human 
adipocytes were transfected on day 6 with pTK-PPRE3x-luc and pRL-CMV.  Transfected 
cells were treated with BSA vehicle, 50 uM 10,12 CLA or 50 uM 10,12 CLA + 50 uM 
RSV (R) for 24 h.  Subsequently, cultures were treated with 0.1 uM BRL for 28 h, and 
then the luciferase activation of the reporter was measured using a luminometer (+ S.E., 
n=3). C: Transfected cells were treated with 1, 10, or 50 uM R for 24 h, and then the 
luciferase measured as in B (+ S.E., n=3).  Means (+ S.E.; n=3) not sharing a lower case 
letter differ significantly (p<0.05).  Data in A-C are representative of at least two 
independent experiments. 
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Figure 5.7.  Working model.  RSV initially blocks 10,12 CLA-mediated increase in the 
levels of ROS and [Ca+2]i, thereby preventing ROS and calcium signaling.  Without these 
signals to activate ERK, JNK, NFκB, inflammatory cytokines, and PGs, PPARγ activity 
is not suppressed.  This allows for normal insulin signaling, glucose and FA uptake and 
metabolism, and TG accumulation in adipocytes.   RSV may also directly activate  
PPARγ. 
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Discussion 
Feeding mixed isomers of CLA, or 10,12 CLA alone, has been shown to reduce 
body fat and the TG content of adipocytes, especially in murine models (House et al. 
2005).  However, adverse metabolic complications (i.e., inflammation, ISR, insulin 
resistance) have been reported with CLA supplementation of humans, particularly for the 
10,12 isomer (Riserus et al. 2002, Riserus et al. 2002, Tholstrup et al. 2007, LaRosa et al. 
2007).  In this article, we demonstrate for the first time that RSV, a phytoalexin with 
antioxidant properties, attenuates markers of inflammation, cellular stress, ROS 
production, insulin resistance, and delipidation in cultures of newly differentiated human 
adipocytes treated with 10,12 CLA.  Central to this mechanism is our discovery that RSV 
blocks 10,12 CLA-mediated  1) increase in [Ca+2]i, which is essential for CLA-mediated 
inflammation and cellular stress (Kennedy et al. 2007), and 2) suppression of PPARγ 
activity in primary cultures of human adipocytes treated with 10,12 CLA.   
Based on these and our previously (un)published data, we propose the following 
working model (Fig. 5.7) by which RSV prevents 10,12 CLA-mediated inflammation 
(Figs. 5.1, 5.2), cellular stress (Fig. 5.3), insulin resistance (Fig. 5.4), and ultimately 
delipidation (Fig. 5.5).  We speculate that RSV initially blocks CLA-mediated ROS 
production or accumulation, and release of calcium from the ER.  This prevents cellular 
stress initiated by ROS and calcium signaling. Without these signals to activate MAPKs 
(e.g., ERK, JNK) and other inflammatory proteins (e.g., NFκB, COX-2, PLA2) or PGs 
(e.g., PGF2α), 1) inflammatory cytokines (e.g., IL-6, IL-1β) and chemokines (IL-8) are 
not induced, 2)  insulin signaling is not disrupted, and 3)  the protein levels and activity 
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of PPARγ and the TG levels are preserved (Figs. 5.5, 5.6).  This allows for normal insulin 
signaling, glucose and FA uptake and metabolism, and TG accumulation in adipocytes.   
Consistent with our data in human adipocytes, 50-150 uM RSV has been shown 
in vitro to reduce inflammation in murine 3T3-L1 adipocytes (Ahn et al. 2007), reduce 
oxidative stress in human lung epithelial cells (Kode et al. 2008, Robb et al. 2008), 
reduce ER stress in mouse macrophages (Tabata et al. 2007), decrease TNFα-mediated 
NFκB activation in hepatocytes (Yu et al. 2008) and coronary arterial endothelial cells 
(Csiszar et al. 2006), and enhance glucose transport in muscle (Park et al. 2007).  Thus, 
RSV reduces inflammation and enhances glucose and FA utilization in vivo and in vitro, 
although the mechanism is unknown. 
Further support for our working model comes from studies showing that RSV 
decreases [Ca+2]i levels following stimulation with various inflammatory agents or 
disease states.  For example, elevated levels of [Ca+2]i induced by severe acute 
pancreatitis was attenuated by RSV (Wang et al. 2008).  Similarly, RSV reduced [Ca+2]i 
levels in stress-induced oxygen-glucose deprivation/reperfusion in primary neurons of 
neonatal rats (Gong et al. 2007).  Lastly, trans-RSV prevented platelet aggregation thru 
inhibiting elevated [Ca+2]i levels (Dobrydneva et al. 1999).  Thus, RSV suppression of the 
levels of ROS and [Ca+2]i may be an important mechanism by which RSV prevents these 
deleterious side effects of 10,12 CLA.   
Alternatively, RSV may suppress inflammation by activating PPARγ.  Support for 
this hypothesis comes from studies showing that RSV activates PPARγ in CaCo2 cells 
(Ulrich et al. 2006) and macrophages (Ge et al. 2006).  Additionally, our data show the 
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RSV robustly induces PPARγ activity and prevents CLA-mediated suppression of TZD-
induced PPARγ activation (Fig. 5.6).  Further support comes from studies showing that 
compounds that enhance PPARγ activity and insulin sensitivity antagonize NFκB-
mediated signaling, and vice-versa (Suzawa et al. 2003, Adams et al. 1997, Ruan et al. 
2003, Nie et al. 2005).  For example, TZDs, which are high affinity PPARγ ligands, 
suppress inflammation (Ruan et al. 2003, Nie et al. 2005).  In contrast, PPARγ depletion 
via siRNA enhances the inflammatory responses of TNFα (Liao et al. 2007).  Consistent 
with these data, Rosiglitazone prevents CLA-mediated insulin resistance and hepatic 
steatosis in rats (Lui et al. 2007, Purushotham et al. 2007), and delipidation of human 
adipocytes (Kennedy et al. 2008). 
One proposed mechanism for the anti-inflammatory actions of PPARγ ligands is 
via (trans) repression of inflammatory gene transcription (Pascual et al. 2005, Ricotte et 
al. 2007, Straus et al. 2007, Ghisletti et al. 2007).  Activation of PPARγ can repress the 
transcriptional activation of inflammatory genes by 1) direct interaction with the mediator 
of transcription (i.e., NFκB, JNK), 2) inhibition of its co-activator recruitment, or 3) 
inhibition of its co-repressor clearance.  For an example of transrepression, ligand-
activated PPARγ becomes SUMOylated, which then binds to co-repressor complexes at 
inflammatory gene promoters, thereby inhibiting dismissal of NCoR/HDAC, which 
blocks inflammatory gene transcription (Pascual et al. 2005, Ricotte et al. 2007).  Notably, 
this pathway does not interfere with transactivation of PPARγ-responsive genes (Pascual 
et al. 2005, Ricotte et al. 2007). Studies are underway to determine if this is the 
mechanism by which RSV prevents inflammation in CLA-treated adipocytes. 
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RSV has also been shown to enhance insulin sensitivity and glucose uptake in 
C2C12 myotubes by enhancing AMPK activity (Ruan et al. 2003).  AMPK is activated 
by adiponectin, and by SIRT1 and PGC1α (Lagouge et al. 2006, Sun et al. 2007). These 
events are directly linked to mitochondrial biogenesis and oxidative metabolism, which 
are positively regulated by PPARα.  Consistent with these data, RSV prevented or 
attenuated insulin resistance and the suppression of SIRT1 and adiponectin mRNA levels 
in CLA-treated adipocytes (Fig. 5.4).  This effect of RSV may be responsible for 
increasing glucose and FA uptake for oxidative metabolism, which we have previously 
shown are suppressed by 10,12 CLA (Brown et al. 2004).   However, we do not know if 
this was due to increased SIRT1 or PGC-1α activation by RSV.   
SIRT1 activation appears to be an important means by which RSV enhances 
glucose and FA utilization, at least in muscle. SIRT1 increases the activation of PGC-1α 
and FOXO1-C, thereby increasing mitochondrial biogenesis and oxidative metabolism 
(Qiao et al. 2006).  Furthermore, several studies demonstrated that feeding 20-400 mg/kg 
body weight/ d of RSV prevents insulin resistance and adiposity in mice fed a high fat 
diet (Baur et al. 2006, Lagouge et al. 2006).  These studies suggest that RSV shifts excess 
calories away from storage in WAT and towards oxidation in muscle and brown adipose 
tissue (BAT), in part, by activating SIRT1.  In contrast to our hypothesis that RSV 
activates PPARγ, SIRT1 overexpression in murine adipocytes decreased PPARγ activity 
and treatment of murine adipocytes with 50-100 uM RSV enhanced FA mobilization and 
release. However, PPARγ activities in WAT of mice or in cultures of adipocytes treated 
with RSV were not investigated (Picard et al. 2004).  Thus, SIRT1 activation by RSV is 
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clearly linked to enhanced glucose and FA metabolism in muscle, and involves AMPK 
activation.  However, the effects of RSV on SIRT1 activation and adipocyte metabolism 
are still unclear, and differences in SIRT1 regulation by RSV between mouse and human 
adipocytes are unknown. 
Taken together, these data demonstrate that RSV prevents 10,12 CLA-mediated 
inflammation, insulin resistance, and delipidation of human adipocytes. Potential anti-
inflammatory mechanisms for RSV include preventing CLA-mediated ROS 
accumulation and release of calcium from the ER, which are associated with cellular 
stress and inflammation, and antagonism of PPARγ activity. Alternatively, RSV may be 
directly activating PPARγ, which has the potential to (trans) repress inflammatory gene 
transcription.  Studies are underway to examine these proposed mechanisms. 
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CHAPTER VI 
 
 
EPILOGUE 
 
 
 
Obesity is an important health issue in the U.S. and world-wide.  Identifying safe 
and effective treatments for obesity is critical for decreasing risk factors associated with 
obesity such as diabetes and cardiovascular disease.  Dietary supplementation with 
conjugated linoleic acid (CLA) has been shown to reduce body fat mass in a number of 
animals such as mice, rats, and pigs.  CLA’s efficacy in humans is still controversial.  
Aside from altering body weight, CLA supplementation has also been reported to 
increase markers of inflammation, induce insulin resistance, and in some cases, cause 
lipodystrophy.  Therefore, it is necessary to understand the mechanism of action of CLA 
in white adipose tissue (WAT), and its potential adverse side effects. 
Our research group has previously demonstrated that 10,12 CLA activates 
mitogen-activated protein kinase / extracellular signal-regulated kinase kinase 
(MEK/ERK) and nuclear factor kappa B (NFκB) signaling.  Activation of these proteins 
induces interleukin (IL)-6, IL-8, and tumor necrosis factor (TNF) α production and 
attenuates peroxisome proliferator activated receptor (PPAR)γ target gene expression, 
leading to reductions in glucose and fatty acid uptake and adipocyte delipidation.  Based 
on these findings, we have investigated 1) 10,12 CLAs impact on PPARγ activity, 2) 
upstream signals (i.e., intracellular calcium [Ca2+]i, reactive oxygen species [ROS], 
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prostaglandins [PGs]) responsible for the activation of NFκB and MAPKs by 10,12 CLA, 
and 3) the role of inflammation and insulin resistance in 10,12 CLA-induced delipidation.     
From these data, I propose (Fig. 6.1) that 10,12 CLA activates a G-protein 
coupled receptor (GPCR) or generates metabolites that activate phospholipase C (PLC), 
thereby increasing levels of diacylglycerol (DAG) and inositol triphosphate (IP3).  These 
proposed signals induce the release of calcium from intracellular stores such as 
endoplasmic reticulum (ER).  The elevation of [Ca2+]i leads to activation of calcium-
calmodulin dependent kinase II (CAMKII), ER stress, and/or mitochondrial dysfunction 
resulting in production of ROS.  These events result in the activation of NFκB and 
MAPKs, which induce inflammation and antagonize PPARγ activity, resulting in the 
suppression of adipogenic and lipogenic genes and insulin resistance and delipidation of 
cultures of human adipocytes.  Based on these findings, I have developed the following 
new questions 1) To what extent to does 10,12 CLA activate GPCRs?, 2) Does 10,12 
CLA activate PLC and increase DAG and IP3 levels?, 3) What impact does 10,12 CLA 
have on mitochondrial and ER function?, and 4) What role does  c-Jun N-terminal kinase 
(JNK) play in 10,12 CLA-mediated inflammation, insulin resistance, and delipidation?   
Q1.  To what extent does 10,12 CLA activate GPCRs? 
Transient increases of [Ca2+]i can occur when a ligand binds to a cell surface 
receptor such as a GPCR.  We have demonstrated that 10,12 CLA increases [Ca2+]i levels 
within 5 min in cultures of human adipocytes.  Also, our research group has demonstrated 
pertussis toxin, an inhibitor of G proteins, attenuates 10,12 CLA activation of ERK.  
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Using data acquired from a microarray gene analysis that I conducted with MERCK 
Pharmaceuticals, I will identify possible GPCR receptors that are induced by 10,12 CLA 
in cultures of human adipocytes.  Once I have identified candidate GPCRs, I will utilize 
PCR to verify the findings from the microarray analysis.  Next, I will perform siRNA 
experiments to knockdown the gene expression of potential GPCRs, and then measure 
[Ca2+]i, inflammatory gene expression, and insulin-stimulated glucose uptake in the 
presence or absence of 10,12 CLA.      
Q2.  Does 10,12 CLA activate PLC and increase DAG and IP3 levels? 
I demonstrated that D609, a PLC inhibitor, attenuated 10,12 CLA increase of 
[Ca2+]i, ROS, and inflammation, suggesting that PLC activity may be involved in 10,12 
CLA-induced inflammation.  The major drawbacks of interpreting chemical inhibitor 
data are that inhibitors are not typically specific for the target of interest.  This was a 
major issue for interpretation of the results in Chapter IV when using KN-62, the 
CAMKII inhibitor, and TMB-8, the inhibitor of calcium release from the ER.  Therefore, 
use of siRNA is more specific for the target of interest.  To investigate the extent to 
which PLC is involved in 10,12 CLA-induced inflammation, insulin resistance, and 
delipidation, I will first measure the phosphorylation levels of the PLC using phospho-
specific antibodies for the four PLC isoforms (PLCβ, PLCγ, PLCδ and PLCε) in the 
absence or presence of 10,12 CLA.  Next, once I determine which PLC isoform is 
phosphorylated by 10,12 CLA, I will utilize siRNA to knockdown the target of interest.  
Once I achieved successful knockdown, [Ca2+]i, markers of inflammation, and insulin-
stimulated glucose uptake will be measured in the absence or presence of 10,12 CLA. 
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PLC generates the lipid-borne second messengers DAG and IP3 from the 
phospholipids PIP2 in response to activation by hormones, growth factors, and lipids.  If 
10,12 CLA is activating PLC, then the levels of IP3 and DAG should be elevated.  To 
investigate this hypothesis, the levels of IP3 will be measured using an IP3 fluorescence 
polarization assay kit from DiscoverX (Fremont, CA).  Cultures of human adipocytes 
cultured in 96 well plates will be treated in the absence or presence of 10,12 CLA. To 
each well quench reagent will be added. The IP3 tracer and binding protein will then be 
added simultaneously. Fluorescence polarization will be measured. Bound IP3 tracer will 
“tumble” more slowly in solution than on-bound IP3, creating a polarized signal (high 
mP).  Also, the levels of DAG and phosphatidic acid will be measured by thin layer 
chromatography. 
Q3.  What impact does 10,12 CLA have on mitochondrial and ER function? 
There is considerable evidence from our research group and others that 10,12 
CLA elicits a stress response in adipocytes.  Currently, it remains to be determined the 
origin of the stress response.  LaRosa et al. (2007) demonstrate that 10,12 CLA increases 
the expression of ER stress-related genes such as XBP-1, eIF2α, and CHOP.  However, 
there was limited protein data in support of these findings.   I investigated 10,12 CLA 
induction of ER stress in cultures of human adipocytes, but was  unable to demonstrate 
activation or induction of key proteins or genes involved in ER stress.  Based on these 
findings, I hypothesized that 10,12 CLA induced mitochondria dysfunction.  I initiated 
studies to investigate the impact of 10,12 CLA on mitochondria function by measuring 
mitochondria membrane potential and release of cytochrome C to the cytoplasm.  The 
120 
findings of these experiments were negative, but there were some issues concerning the 
dye used to measure membrane potential.  Particularly, the dye aggregated towards the 
lipid droplets making it unclear to decipher whether the dye was staining the 
mitochondria or areas around the lipid.  Therefore, another approach I will take is to 
measure oxygen consumption in adipocytes treated with 10,12 CLA  using oxygen 
sensitive plates. 
Q4.  What role does JNK play in 10,12 CLA induced inflammation, insulin resistance, 
and delipidation? 
I recently discovered that 10,12 CLA increases the phosphorylation levels of JNK 
and it’s downstream target cJun, a member of the redox-sensitive transcription factor 
activating protein-1 (AP-1), that induces inflammatory gene transcription and cell 
survival.  Notably, I found that the polyphenolic compound resveratrol blocked 10,12 
CLA activation of JNK.  Data acquired from a microarray gene analysis demonstrated 
that 10,12 CLA increased the gene expression of JNK and cJun, and resveratrol 
attenuated this induction.  Based on these preliminary data, I hypothesized that 10,12 
CLA activation of JNK is a key player in 10,12 CLA-mediated inflammation, insulin 
resistance, and delipidation.   
To investigate the role of JNK, the isomer-specific effects of 10,12 CLA on the 
activation of JNK and cJun will be determined in the presence and absence of specific 
chemical inhibitors of JNK (i.e., SP600125) and siRNA targeted to JNK1 and 2, followed 
by immunoblotting for JNK and cJun using phospho-specific antibodies. The impact of 
JNK activation on 10,12 CLA’s induction of proinflammatory genes (i.e., IL-8, IL-6, IL-
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1β, COX2, and ATF3) and suppression of lipogenic and adipogenic genes and protein 
expression (i.e., PPARγ, GLUT4, adiponectin, ACC, and LPL) will be measured.  The 
impact of these JNK inhibitors and siRNA targeted to JNK1 and 2 on insulin-stimulated 
glucose uptake and delipidation will also be investigated. 
In conclusion, further investigation of potential upstream signals responsible for 
calcium release and ROS production needs to continue.  These studies will provide 
mechanistic insights for delineating the role of isomer-specific role of 10,12 CLA for the 
prevention or treatment of obesity and inflammation, and identifying lipid-borne signals 
induced by CLA that regulate glucose and lipid metabolism in human adipocytes.   Thus, 
we will gain more knowledge for the development of therapeutic treatments for obesity 
and metabolic diseases. 
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Figure 6.1.  Working Model-10,12 CLA’s antiobesity mechanism of action in 
adipocytes. 10,12 CLA activates a GPCR or generates metabolites that activate PLC 
thereby increasing levels of DAG and IP3.  These proposed signals induce the release of 
calcium from intracellular stores such as ER.  The elevation of [Ca2+]i leads to activation 
of CAMKII, ER stress, and/or mitochondrial dysfunction resulting in production of ROS.  
These events result in the activation of NFκB and MAPKs, which induce inflammation 
and antagonize PPARγ activity, resulting in the suppression of adipogenic and lipogenic 
genes and insulin resistance and delipidation of cultures of human adipocytes. 
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